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Abstract 
Background: Micronutrient supplements are a formulae comprised of essential nutrients 
including: vitamins, minerals and amino acids. 
Objective: This study investigates the composition of micronutrient supplements and the 
differences found between micronutrient supplements used in child focused research and 
supplements available over the counter. This study also aims to explore the reasons for 
which New Zealand parents give their children micronutrient supplements.  
Methods: These areas are explored in two separate investigations. The first study begins by 
identifying the psychologically based micronutrient literature, then brakes down the vitamin 
ingredient composition of the micronutrient supplements that are found to significantly 
improve behaviour or cognition in children. These findings are compared to the composition 
of over the counter commercial micronutrient supplements. The second study had 365 
participants and was carried out in the form of a web-based survey. 
Results: A number of studies were found that showed significant behavioural or cognitive 
improvements in children as a result of micronutrient supplementation. The median vitamin 
daily doses from the effective supplements were found to be greater than the daily doses 
found in the over the counter products. This difference was found to be significant for most 
of the B vitamins: B1 (p <.05), B3 (p<.05), B5 (p<.001), B6 (p<.05), B7 (p<.05), B9 (p = .001), 
B12 (p <.05). The difference was also found to be significant for vitamin C (p <.05) and 
vitamin D (p <.05). The difference between the research and commercial supplement 
median doses was not found to be significant for vitamin A (p <.3) or vitamin B2 (p <.2). The 
web-based survey revealed that New Zealand parent’s do not in general, give their children 
micronutrient supplements for psychologically based reasons. The most common 
motivation for giving their child a micronutrient supplement was found to be for the 
prevention of colds and illnesses. 
Conclusions: Micronutrient supplements that are effective in research with a child based 
psychological focus have in general significantly greater vitamin dosages than commercially 
available supplements. This indicates that the results found in scientific micronutrient 
studies may not be generalisable to over the counter supplements. Comparing the 
ingredients and dosages in micronutrient supplements is however, a complex process and 
further investigation is required. Furthermore, this research showed that micronutrient 
supplements appear to be given to New Zealand children for purposes that are not 
psychologically based, but are based more on physical health. 
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Introduction 
1. Micronutrients Introduction 
Over the last decade interest has slowly developed in the use of micronutrients to 
influence psychological functions. To date, micronutrient research has been varied across 
the psychological areas of mood, behaviour and cognition. The repeated finding of 
successful amelioration of psychological functions has greatly increased the use of 
micronutrients in the approach to treating psychiatric disorders. The rationale behind 
focusing on multi-ingredient micronutrient supplement is based on the premise that the 
mechanism of action of micronutrients might involve additive or synergistic effects of 
complex mixtures. Humans evolved to require a mixture of nutrients, hence dietary 
interventions of single ingredients may risk upsetting the balance of nutrients and creating 
deficiencies in other nutrients (Mertz, 1994). Therefore, a natural intervention approach to 
evaluate might be a broad array of well-balanced micronutrients, and the administration of 
these nutrients together provides an excellent opportunity to examine how nutrients may 
work in combination.  
Micronutrients are substances required in small amounts examples include vitamins, 
minerals and some amino acids, they are crucial for normal and healthy bodily function 
(Institute of Medicine, 2001). This is in contrast to macronutrients which are required in 
larger amounts; for example, some proteins, fats and carbohydrates (Institute of Medicine, 
2001). The absence of a vitamin blocks one or more specific metabolic reactions in a cell and 
eventually may disrupt the metabolic balance within a cell and in our entire body, making 
their role an essential one (MacWilliam, 2009). For the purposes of this study a 
micronutrient supplement was defined as a supplement containing three or more vitamins 
and/or minerals and/or amino acids, and named the supplement a multi nutrient, or multi 
vitamin and/or mineral, or a micronutrient supplement. 
Micronutrient supplements are regulated in NZ law under the Dietary Supplements 
Regulations (1985), which was amended in 2010. A substance is a dietary supplement based 
on its ingredients, its purpose and the manner in which it is presented to the market 
(Dietary Supplements Regulations, 1985). The product must be taken orally in a 'therapeutic 
type’ dose form, and abide by the recommended daily intakes on a number of vitamin and 
9 
 
mineral daily dosages. The maximum daily dosage regulations in New Zealand for products 
designed for children adopted from the US Food and Nutrition Board of the National 
Academy of Science. The NZ regulations have no specific restrictions on the psychological 
claims supplements can imply. A number of commercial micronutrient manufacturers make 
advisories that they promote an aspect of mental or emotional well-being and yet there is 
no requirement for provision of evidence to support such advisories. 
The supplements used in child-focused micronutrient studies are not those found in 
supermarkets, pharmacies or health-food stores, but are high end products available solely 
on-line direct from the producing company, or were created specifically for research 
purposes. It was not clear prior to this investigation whether the supplements used in 
studies have comparable compositions to those sold over the counter. This study aims to 
identify a broad range of micronutrient products for children that are available over the 
counter, and compare them in both ingredients and dosages to supplements used in 
research studies that produce significant behavioural symptoms reduction or improve 
targeted areas of mood or cognition.  
The comparison of research and commercial supplements will highlight whether 
there are significant differences in dosages or ingredients between formulations used in 
research compared to over the counter supplements. The resulting findings might indicate 
the applicability of micronutrient research results to common New Zealand household 
micronutrient products. This may be informative for those wanting to provide New Zealand 
parents with information make better choices when purchasing micronutrient supplements. 
Through this investigation it will also be possible to identify any commonalities across the 
research and commercial supplement ingredients and investigate possible reasons behind 
the common inclusion or exclusion of the ingredient(s). An example of this is a vitamin or 
mineral that is included across all, or almost all supplements. If common components are 
identified this might provide useful information about mechanisms of pharmacological 
action, and in turn, possibly provide information for the development of useful products (ie. 
which have a pharmacological rationale for their activity) in the future.  
There may be a number of conceptual frameworks that explain the previous 
literature findings of behavioural change as a result of micronutrient supplementation, and 
the potential mechanisms of action need not be mutually exclusive. Inborn errors of 
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metabolism can have many effects, including influencing enzyme/coenzyme reactions and 
ultimately brain function (Kaplan et al., 2007). One third of genetic mutations are known to 
result in an enzyme having decreased binding affinity for a coenzyme, and it is possible that 
brain dysfunctions such as unstable mood represent a type of genetic mutation, whereby 
the individual requires higher amounts of specific micronutrients for normal metabolic 
functioning (Ames, 2004). It is also established that nutrients can alter gene expression so 
(Kaplan et al., 2007) for example, colorectal cancer patients. Pufulete, et al. (2005) found 
that a folic acid supplement significantly reversed the inadequate DNA methylation present 
in the cancer patients, hence altering gene expression.  
A further mechanism of action by which micronutrient supplements achieve 
pharmacological results may be the B vitamins structure activity relationships (SARs) with 
dopamine (Shaw et al., 2010). Dopamine is involved in a number of psychological disorders 
including schizophrenia, ADHD, addiction and psychosis (Kapur, 2003; Shaw et al., 2010). 
The therapeutic effect of Ritalin (methylphenidate) in the treatment of attention deficit 
hyperactivity disorder (ADHD) is thought to be linked to its effects on norepinephrine and 
dopamine(Shaw et al., 2010). The motor dysregulation characteristic of ADHD may be 
attributed to dopamine depletion prefrontal-striatal-thalamic-cortical pathways that project 
through either the internal or the external segment of the globus pallidus, which leads to 
difficulty in initiating movement or excess motor activity (Solanto, 2002). Insufficient levels 
of dopaminergic activity are also believed to be primarily responsible for the cognitive 
symptoms of the disorder. This is hypothesised due to the improvements found when 
treated with stimulants such as methylphenidate that may reduce dopamine depletion 
(Mchta et al., 2001). The formulae found to effectively ameliorate the symptoms of ADHD 
following long-term dosing, include an array of B vitamins, biotin and related compounds 
(Shaw et al., 2010). An example of this outlined by Shaw et al. (2010) where they postulate 
that vitamin B1 may occupy the dopamine transported (DAT) binding site, reducing the 
efficiency of dopamine transport from the synapse. This increases the synaptic dopamine 
level, consequently having pharmacological effects similar to methylphenidate (Ritalin©). 
This means that vitamin B1 may behave pharmacologically in a similar manner to 
methylphenidate and thus ameliorate the symptoms of ADHD. 
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Of the B vitamins, three; namely B6, B9 and B12, have been linked to reductions in 
homocysteine levels (NHMRC, 2006). Homocysteine is a natural amino acid synthesised at a 
particular point of the methylation process. Methylation denotes the addition of a methyl 
group to a substrate, or the substitution of an atom or group by a methyl group. An 
oversupply or accumulation of homocysteine has been directly linked to heart disease and 
depression related symptoms (Folstein et al. 2007).  
It is clear that there are a number of possible mechanisms of action that may be 
responsible for the observed psychological effects of micronutrient treatment, and these 
mechanisms may vary across different nutrient combinations. Future exploration of these 
potential mechanisms of action is vital to providing effective treatments with the best 
possible outcomes for an individual’s circumstances. 
1.1. Research on the Use of Micronutrients.   
A 1997 survey of American children indicated that 54% of all three year olds are 
given a dietary supplement, and of those children, 85.4% are given a micronutrient 
supplement (Yu et al., 1997). Yu et al. (1997) also showed that the child health 
characteristics associated with supplement use included first birth order, having selective 
eating behaviours or poor appetite, or chronic health problems. In a US based study, Rock 
(2007) found adolescents to have a lower use of micronutrient supplements and dietary 
supplements in general.  They also found adolescent supplement use to be associated with 
being female, having a lower intake of total and saturated fat and higher dietary nutrient 
intakes. Maternal characteristics found to be associated with child micronutrient 
supplement use are mothers that are older, more educated, have greater household 
income, take supplements during pregnancy, and are non-Hispanic white (Yu et al., 1997). 
Unfortunately, these investigations suggest that youths that may have a greater risk of 
nutrient deficiency due to their socioeconomic (SES) circumstances, are less likely to take a 
supplement. 
The European Prospective Investigation into Cancer and Nutrition (EPIC) study 
analysed the dietary intake of persons aged between 35 and 74 years in 10 western 
European countries (Olsen et al., 2009). These countries included Denmark, France, 
Germany, Greece, Italy, Norway, Spain, Sweden, the Netherlands and the United Kingdom. 
They found that the most systematic variation in dietary food intakes (excluding supplement 
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use) related to the B vitamins. Across the 10 countries and almost all regions within these 
countries, after adjustment for energy intake and body composition, men were found to 
have substantially higher B vitamin intakes than women. Olsen et al. (2009) found that 
education has also linked to vitamin intake, although in this case dietary intake excluded 
supplement use. Olsen et al. (2009) showed that education was positively associated with 
vitamin C intake in both men and women and to vitamin B6 intake in women.  
In summary, research has found that micronutrient use is common, and adults and 
adolescents with suboptimal nutrient intakes from food sources are less likely to be dietary 
supplement users. Research to date suggests that a large portion of children, ie. 
approximately 46% (Yu et al., 1997) take a micronutrient supplement; therefore, it would be 
useful to understand parental motivation for giving a supplement to their children. 
Scientists have showed the percentage of children taking micronutrients, and the 
demographics of the child and the parent, but not what motivates parents to purchase a 
micronutrient supplement. If parents are motivated to buy a supermarket or pharmacy 
micronutrient supplement based on the belief they provide mental or emotional benefits 
for their child, it is also important to examine the validity of these beliefs.  
 
1.2. Current Study Purpose 
The purpose of this study is to explore the answers to two key questions. Firstly, 
through product comparisons previously mentioned, establish if the micronutrient products 
designed for children that are sold over the counter in New Zealand are likely to provide any 
mental or emotional benefits to our children, through a comparison with the micronutrient 
research to date. Secondly, to identify the motivations of New Zealand parents when they 
purchase a micronutrient supplement for their child. This part of the research will be 
conducted in the form of an on-line survey. The survey will also attempt to identify the 
micronutrient brands of choice of New Zealand parents, factors that influence their 
purchasing, and identify any benefits that parents have perceived as a result of their child’s 
micronutrient use.  
The two main components of this research are exploratory as there has been no 
previous investigation into these specific areas. For part one of this study, the investigation 
was based on a brief preliminary examination of research and commercial supplements. It 
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was hypothesised that the dosages used in micronutrient studies would have different 
ingredients and average dosages higher than the commercial dosages in micronutrient 
supplements. The investigation for part two of this study was based upon initial questioning 
of parents as to why they brought a micronutrient supplement for their child. These 
preliminary questions led to the hypothesis that the majority of parents in New Zealand 
were not purchasing a micronutrient supplement to improve their child’s psychological well-
being.  
 
2. Mental Health Micronutrient Literature Review 
 
The formulation and proven efficacy of safe and well tolerated effective treatments 
for psychological disorders and mood and cognition, is a priority of both practitioners and 
researchers, however psychologically focussed randomised placebo controlled 
micronutrient trials for children remain relatively limited. A review of the micronutrient 
research that has been conducted with the youth population indicates improvements in 
symptoms of bipolar disorder (Rucklidge et al., 2010; Kaplan et al., 2004), schizophrenia 
(Joshi and Eswaran 1980), and autism (Mehl-Madrona et al., 2010). Other benefits resulting 
from micronutrient administration have also been found in mood and general behaviour 
(Kaplan et al., 2002; Kaplan et al., 2004), and IQ (Schoenthaler et al., 1991; Benton, & Cook 
1991).  
After a search of the scientific literature, each of the following sections outlines  the 
research conducted into the effects of micronutrient supplements on children as discussed 
above. The lack of randomised controlled trials meant that to obtain the best indication of 
micronutrient effectiveness, all types of studies were included in the analysis. Overall, the 
findings were generally positive, both the studies that found a positive effect, and those that 
found a non-significant or negative outcome, are outlined in each section.  
 
2.1. Paediatric Bipolar Disorder (BPD) 
BPD is a psychiatric mood disorder characterised by periods of elevated mood 
clinically labelled as mania, sometimes accompanied by periods of depressed mood. 
Micronutrient treatment has been found to lead to a reduction in a number of paediatric 
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bipolar disorder symptoms. There have been a total of three studies. Of these three studies 
all found a reduction in symptoms. One of these studies did not use psychometrics to 
measure this change; consequently significant reductions are outlined for two of the three 
studies. Micronutrient supplementation has been found to lead to symptom reductions in 
hallucinations, sleep problems, tantrums, depression, mania, compulsions, mood and 
anxiety. All three of these micronutrient BPD studies used a micronutrient product called 
EMPowerplus. 
EMPowerplus is the most frequently used supplement in psychologically focussed 
micronutrient research. It is a 36 ingredient, broad spectrum micronutrient formula that 
includes vitamins, minerals, and plant nutrients, apparently designed to provide nutritional 
support for the central nervous system. A safety and tolerability review that incorporated 
the findings from thirteen different reports of mental health research involving 
EMPowerplus was recently published (Simpson et al., 2011); they found the micronutrient 
formula EMPowerplus to be associated with no occurrences of clinically meaningful 
negative outcomes, and only minor transitory physical side effects such as headaches or 
nausea. The one experiment that allowed for direct comparison between the micronutrient 
treatment group and the medication group, found significantly fewer adverse events and 
less weight gain in the micronutrient group compared to the medication group (Simpson et 
al., 2011). They also highlighted that EMPowerplus was consistently related in the literature 
to an enhanced response to pharmaceuticals, especially for patients with depression or 
bipolar disorder.  
The case study that did not use psychometrics to document change, (Frazier et al., 
2009) was based on a boy diagnosed with bipolar disorder at age six. The boy’s disorder had 
escalated in severity and he had developed psychotic features, generalised anxiety and 
obsessive-compulsive disorder (OCD) by age ten. His conventional medication was changed 
often due to intolerable side effects or inadequate treatment response, and no medication 
maintained a desirable mood balance or a consistent improvement in symptoms over an 
extended period of time. At age 12 over the period of a month, he was transitioned off his 
psychotropic medications and onto a full dose of EMPowerplus. Following this transition 
period his global functioning notably improved, his sleeping, peer interactions, anxiety and 
focus improved, his compulsions decreased and hallucinations ceased. His parents stated 
that the improvements in his functioning were greater than those he made in the past on 
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other medications. In the subsequent nine months these symptom improvements were 
maintained, allowing the child to attend public school for the first time. Although 
standardised data collection did not occur in this case report, the longitudinal nature of the 
clinical record supports the observed effects of EMPowerplus. 
Rucklidge, et al. (2010) analysed the data provided by people who purchased 
EMPowerplus for their children under the age of18. The 120 participants had been 
previously diagnosed with either PBD or PBD with ADHD. Data was analysed from three to 
six months post baseline. In some cases medications were reduced as the micronutrient 
supplement was introduced. The median dose of the micronutrient formula at the Last 
Observation Carried Forward (LOCF) was 13.7 capsules daily. The LOCF for those with PBD 
indicated a 46% decrease in symptom severity from baseline (effect size = 0.78 cohen’s d, p 
< 0.001). For those children with PBD and ADHD, symptom severity reductions from baseline 
were similar to those participants with PBD alone, with a 43% reduction in PBD symptoms 
and a 40% reduction in ADHD symptoms. These findings were consistent across both age 
and gender. This study was limited by its open label nature, the inherent self-selection bias, 
the use of parent report only, and the lack of a control group. The results however, suggest 
micronutrients may enable children to reduce their psychiatric medications, and improve 
their psychiatric symptoms with minimal side effects.  
Frazier et al. (in press) conducted an open label micronutrient trial using 
EMPowerplus that involved children between the ages of 6 and 12 years with BPD. They 
found significant decreasing trends in both depression and mania from baseline, during 
eight weeks of micronutrient administration.  From the beginning of treatment through to 
the final visit, a 37% decrease in depression scores (p< 0.06) and a 45% decrease in mania 
scores (p< 0.01) were revealed by intent to treat analysis. Minor temporary side effects 
were experienced, most often in the form of gastro discomfort.  
Overall results suggest micronutrients may provide a reduction in a number of 
paediatric bipolar symptoms, although from this research it is not clear which symptoms 
may be most sensitive to micronutrient supplementation. Clearly, much more research is 
needed in this area, as preliminary studies indicate micronutrient supplements may provide 
significant improvements in symptoms, with limited side effects. 
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2.2. Autism Spectrum Disorder (ASD) 
  Autism Spectrum Disorders (ASD’S) are heterogeneous neurodevelopmental 
disorders. ASD’s are complex disorders with a strong genetic component, and are likely to 
have a number of causes, (Skaar et al 2005).  Autism has is becoming increasingly more 
common, highlighted by a recent study which identified that approximately 1 in 91 children 
in America is diagnosed with an ASD (Kogan et al., 2007). Therapeutic intervention in this 
disorder varies according to individual circumstances. Treatments with vitamins, some 
amino acids, minerals and other nutritional supplements have recently emerged as effective 
treatment options for ASD symptom reduction for some children (Adams, 2007). These 
treatments may be effective because psychiatric symptoms in ASD may represent an inborn 
metabolic dysfunction which is associated with slowed metabolic activity due to suboptimal 
availability of micronutrient cofactors (Ames et al 2002).  
Children with autism are particularly at risk for nutrient deficiencies in a range of 
nutrients essential for brain function, largely due to the abnormal self-restrictive eating 
habits that this population tend to demonstrate, often resulting in reduced intake of a wide 
variety of foods. Through blood test analysis, Adams, et al. (2003) found that children with 
ASD had on average much lower levels of most vitamins: vitamins A, C, D, and E and all B 
vitamins except choline, when compared to age-matched controls.  
The most successful and rigorously tested of the vitamin and nutritional therapies is 
a vitamin B6 (pyridoxine) and magnesium combination (Rimland 1987; Rimland, 1988; 
Martineau et al 1988). Vitamin B6 is required for over 100 enzymatic reactions, including the 
production of major neurotransmitters such as serotonin and dopamine, and glutathione 
which is required for detoxification (Rolfes et al., 2006). Magnesium is used in this 
treatment setting to prevent the possibility of hyperactivity, which can occur if vitamin B6 is 
taken by itself. The effectiveness of this treatment could be related to the actions of both 
vitamin B6 and magnesium as nutrients themselves, or the mechanism of action for these 
nutrients may be due to their influence on reactions that affect a number of 
neurotransmitter systems which may be implicated in autism (Martineau et al 1985). The 
high dose B6-magnesium combined studies found an average of around 45-50% of children 
and adults with autism benefited from the treatment (Pangborn et al., 2005).  
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In the most recent micronutrient studies the effects of nutrients on ASD symptoms 
are further supported. There have been four micronutrient studies, all of which have found 
a positive effect. These studies are in a variety of different forms including a case study, a 
naturalistic open label case study and two randomised placebo controlled trials. The case 
study involved an un-medicated nine year old boy with ASD (Xia, 2011). Xia (2011), found 
that scores on the Autism Evaluation Checklist reduced from baseline following five months 
of supplementation by 47.6% and 53.1%; as rated by two independent assessors. The 
supplement contained an amino acid analogue called dimethylglycine (DMG; 375 mg daily), 
vitamin B6 (pyridoxine HCl; 37 mg daily) and magnesium (magnesium citrate-glycinate-oxide; 
180 mg daily). A noticeable change in the boy’s behaviour was also reported by his school 
teachers and parents. Two years since the beginning of nutritional supplementation the 
participant’s symptom improvements were retained with no-side effects observed. 
Although these results cannot be generalised, the findings provide evidence that support 
the effectiveness of using nutritional supplements when treating ASD.  
In a group of typical children not taking supplements and of a similar age pre-
supplementation vitamin B6 levels were measured by Adams and Hollaway (2004) in both 
the placebo and supplement group. Prior to taking the supplements, the placebo and 
supplement group had similar vitamin B6 levels which were well above the typical reference 
range for typical children at this age. The typical reference range was consistent with the 
average level of B6 in the typical children whom were tested. The difference in total vitamin 
B6 levels between the ASD group and the typical children was highly significant (p < 0.001). 
This elevated level implies a functional need for more vitamin B6 in those with ASD’s, and 
may explain why high doses of vitamin B6 have been shown to benefit children with an ASD. 
In a randomised, double blind, placebo controlled trial Adams and Holloway (2004) 
administered Spectrum Support, a supplement available on the internet direct from the 
company BrainChild Nutritionals, which contains a broad array of vitamins and minerals. 
This supplement was administered over three months to eleven children with ASD (Adams & 
Hollaway, 2004). The mean age of the eleven participants and of the nine controls was 5 
years of age. No adverse side-effects were reported when the dosage instructions were 
followed. At the end of the study there were no significant improvements in any areas of 
the Global Impressions scale in the placebo group. Those children who received the 
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supplement had significant improvements in their sleep and gastrointestinal symptoms (p < 
0.05).  
Adams, et al. (2011) conducted a randomised, double-blind, placebo controlled trial 
with a micronutrient supplement that was administered over 3 months to 141 children and 
adults with autism. The overall average age of the participants was between 9 and 13 years 
old. Of the 141 participants, 53 were children aged between five and sixteen and had their 
nutritional and metabolic status measured pre and post treatment. The comprehensive 
supplement contained most vitamins and minerals and did not include iron or copper, as the 
researcher’s had determined from previous research that these two minerals were not 
needed by most children with autism. The dosage of B6 was deliberately set high at 40mg. 
This is high when compared to the New Zealand recommended daily allowance (RDA) for 
B6of 1mg. At post-test the supplement group demonstrated significantly greater 
improvements than the placebo group on the Parental Global Impressions-Revised (PGI-R) 
(p < 0.01), and on the sub-scores of hyperactivity (p < 0.01) and tantrums (p < 0.01). The 
PGI-R was used because it assesses changes in symptoms. On three additional measures 
there were no significant differences between the supplement and placebo group. The 
nutrition and metabolic status of the children measured in the supplement group was found 
to significantly improve to normal or near normal levels in the areas including methylation, 
glutathione, oxidative stress, and sulfation. 
EMPowerplus or a supplement customised to match EMPowerplus was used by 
Mehl-Madrona et al. (2010) in a naturalistic open label case study of children with ASDs. The 
trial consisted of two well matched groups: the micronutrient group (44 participants) and 
the medication group (44 participants). If already on medication the participants in the 
treatment and comparison groups continued their normal medication throughout the trial. 
The mean age of the groups was between eight and nine years of age. The micronutrient 
group received EMPowerplus (or similar), and were found to have significantly greater 
symptom declines in a range of areas when compared to the medication alone group. Areas 
where the change from baseline was significantly greater for the micronutrient group than 
the medication group included activity level, withdrawal, angry affect and unspontaneous 
relation to the examiner.  The micronutrient group’s improvement on the Aberrant 
Behaviour Checklist was significantly greater than that of the medication group (p < 0.0001), 
the same was true on the Clinical Global Impressions scale (p < 0.01). A significant reduction 
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in self-injurious behaviour intensity was found in the micronutrient group and not the 
medication group after the final appointment (p < 0.01). There were no areas of 
symptomology that improved significantly more in the medication group than the 
micronutrient group. Overall side effects including adverse events and weight gain were also 
much less in the micronutrient group with 33 adverse events in the micronutrient group 
compared to 214 recorded in the medication group.  At the end of the trial the number of 
medications consumed by the two groups was significantly different (t = -6.19, p < 0.0001). 
The mean number of pharmaceutical pills consumed by the micronutrient group was 0.59 
daily (SD =0.95), in contrast the mean number for the medication group at the end of the 
supplement administration period was 2.23 daily (SD=1.48). This study highlights a number 
of possible benefits resulting from micronutrient supplementation. Benefits include 
improved symptoms, reduction of reliance on pharmaceutical medication, and a reduction 
in adverse side effects when used to treat children with ASDs. 
Autism is a complex disorder. There are however, many biomedical abnormalities 
that have been identified, and although it is unlikely that there will be one general 
metabolic therapy that would improve symptoms in all cases of ASD, micronutrient 
treatments for autism appear to be effective. The evidence so far suggests micronutrients 
are a legitimate treatment used alone, or as a supplementary treatment for some children 
with ASD’s. Further research is needed to verify the efficacy of these treatments and 
identify those with ASD who will respond best to nutrient supplementation. 
 
2.3. Attention Deficit Hyperactivity Disorder (ADHD) 
  ADHD is characterized by problems with inattention, hyperactivity, and impulsivity 
and is one of the most prevalent developmental disorders in childhood. Finding effective 
treatments with minimal side effects is a goal of both researchers and practitioners. 
Prevalence rates of ADHD in Australia were estimated to be around 11% in 2011 (Sawyer et 
al., 2001), and around 4.4 million school aged children in the US are reported to have a 
history of ADHD diagnosis, many of whom take medication (Bloom & Cohen, 2007). ADHD 
normally manifests before the age of seven, and the problems associated with this disorder 
include adverse effects on school performance and peer and family relationships. ADHD is 
also associated with cognitive deficits, specific learning disabilities, poor self-esteem and 
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more than half of these children experience co-morbid psychiatric problems (Biederman, 
1997).  
There have been three studies involving micronutrients in this area. Of these studies 
two have found significant positive effects, and one found no added benefits resulting from 
supplementation. The first of these studies directly compared pharmaceutical medication 
with a micronutrient supplement. Harding, Jadah and Gant (2003) compared the symptom 
changes in 20 children with ADHD between the ages of 7 and 12. Ten children were self-
selected into the Ritalin© treatment group; the other ten were self-selected into the dietary 
supplement group. The supplement used in the alternative treatment group was specifically 
created for the trial and contained a multitude of vitamins and minerals, essential fatty acids 
(EFAs), phospholipids, probiotics and amino acids. The Intermediate Visual and 
Auditory/Continuous Performance Test (IVA/CPT) was the primary outcome measure used 
to measure symptom change. The IVA/CPT assesses response inhibition and attention 
problems, and unique to this test measures both auditory and visual distractibility. This test 
has high reliability and validity in diagnosing and assessing ADHD treatment efficacy as well 
as medication titration. After four weeks of treatment, comparative analysis found there to 
be no significant differences in the level of improvement between the Ritalin© and 
supplement groups. Both groups showed significant gains (p < 0.001) on the full scale 
response control, and full scale attention control quotients. Despite the possible self-
selection bias in this research, the results indicate that micronutrient supplements may have 
similar effectiveness to Ritalin© in the treatment of ADHD symptoms.  
 There have been limited placebo controlled trials investigating the effects of a 
micronutrient supplement on ADHD symptoms. In one placebo controlled trial, the above 
findings are supported by Katz et al. (2010). They found that treatment with a broad base 
micronutrient supplement called Nurture and Clarity, led to significantly greater ADHD 
symptom improvements when compared to a placebo group. The 120 participants were 
randomly assigned to the treatment or placebo group in a two to one ratio respectively. 
Participants were children aged between 6 and 12 years of age, and were newly diagnosed 
with ADHD and had no history of previous ADHD treatment. Participants were excluded if 
they did not meet the symptom severity threshold set, or if they had any additional medical 
conditions or illnesses, any co-morbid psychiatric conditions or were using any type of 
medication. This randomised, double blind, placebo controlled trial was conducted over four 
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months. The micronutrient formula contained EFAs, phospholipids, amino acids, B-vitamins, 
minerals and other micronutrients. At the four month follow-up, the treatment group 
demonstrated highly significant improvements (p < 0.001) in all four dimensions of the Test 
Of Variables of Attention (TOVA: a test used to detect changes in the variables of attention) 
as well as the overall TOVA score. These findings were in contrast to the placebo group, 
where no significant changes in any of the test dimensions were found. After adjustment for 
age, sex and baseline TOVA score, treatment differences between the groups in each of the 
four subscales persisted strongly. The most significant group differences were found in 
response time and variability. Throughout the trial no serious adverse events were reported, 
and any mild, transient adverse events reported did not persist past the first two weeks. At 
follow-up, 73 participants remained in the treatment group, and 19 children remained in the 
placebo group, a statistically different completion rate (p < 0.0001), which suggests that 
participants possibly perceived their lack of improvement in the control group and 
consequently guessed their group allocation. Importantly, the baseline characteristics of the 
two groups were similar, which helps to alleviate the possible concern of selection bias. This 
study provides further evidence that micronutrient treatment may provide a safe, well 
tolerated therapy that effectively improves the symptoms of ADHD, increasing its potential 
as a valuable ADHD treatment option. 
 Further research is required to replicate the findings in the discussed micronutrient 
ADHD studies, this need is highlighted by by Sinn and Bryan (2007) who found no additional 
symptom improvements when a multivitamin supplement was added to a polyunsaturated 
fatty acid (PUFA) supplement for ADHD children. The micronutrient supplement 
administered contained 12 vitamins and 7 minerals. The vitamin dosages used were 
comparable to over the counter commercial supplements. Sinn and Bryan hypothesise that 
the absence of additional benefits was likely contributable to the low multivitamin dosages 
used. They speculate that the dosages were too low to result in any significant changes in a 
clinical sample. Further research is needed to identify the specific nutrients, and the dosages 
in micronutrient supplements that are effective in ameliorating the symptoms of this clinical 
population. 
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2.4. Mood & General Behaviour 
There have been a limited number of placebo controlled trials in the area of 
micronutrient formulas, but a variety of types of studies provide important links between 
micronutrients and their effect on mood symptoms. There have been three micronutrient 
studies, including a case study, a case series and one randomised placebo controlled study. 
All of these studies reported positive results. As only two of the three studies collected 
quantitative data, significant effects resulting from micronutrient treatment are discussed 
for only two of the three studies.  
The case study had an open label ABAB reversal treatment format. Kaplan et al. 
(2002) found that micronutrient treatment lead to reductions in mood lability and explosive 
rage. Two boys were given the old formulation of EMPowerplus and at full dosage they 
were taking eight capsules four times daily and were on no medications throughout the 
duration of the case study. The first subject, an eight year old boy, had been previously 
diagnosed with atypical OCD, ADHD, mood lability and explosive rage. The second boy, 12 
years of age, had been diagnosed with pervasive developmental disorder with Asperger 
characteristics, and exhibited severe ADHD, learning problems, mood problems and 
explosive outbursts. To assess symptom change, parents evaluated their children’s 
behaviour on a modified Connors Parent Rating Scale. The two items that were measured 
were: mood changes quickly and drastically; and temper outbursts, explosive, and 
unpredictable behaviour. A minimum of one week baseline monitoring preceded the 
introduction of the micronutrient supplement. Mood, angry outbursts and obsessional 
symptoms that improved when initially receiving the supplement, returned to baseline 
levels when not taking the supplement, and remitted when the micronutrient product was 
reintroduced. No adverse effects of the micronutrient supplement were noted by either the 
children or their parents. The second boy did however begin to struggle with taking the 
large number of capsules daily. The new version of EMPowerplus addresses this problem, as 
the volume of pills required at a full daily dosage has been greatly reduced.  
Remaining on a maintenance dose of just eight capsules daily (25% of the full dose) 
the improvements in these symptom areas were maintained two to three years following 
the beginning of the trial. Two years following the treatment initiation the second boy 
began a dose of 15mg dextroamphetamine to help in focus on school days, suggesting that 
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the micronutrient supplement alone was not sufficient to address his inattention 
specifically. The clinical effectiveness of this micronutrient supplement is strongly supported 
by the withdrawal and reinstatement of the supplement and the supporting changes in 
mood and behaviour. Importantly, the long term stabilisation of mood and behaviour 
changes achieved with a lower maintenance dose also means that the initial large number 
of capsules taken daily is not necessary to maintain symptom changes for the long term.  
 In further support of the Kaplan et al. (2002) case study, is an open label case series 
on nine children aged between eight and fifteen years of age with mood and behavioural 
problems. The participants were clinically diagnosed with an anxiety, mood, or behavioural 
disorder, and had a well-documented clinical history of symptomatology, and were all on a 
stable psychiatric medication regimen. The micronutrient supplement administered was the 
old version of EMPowerplus and the full dose given was eight capsules taken four times 
daily for eight weeks. As measured on the Child Behaviour Checklist (CBCL) statistically 
significant improvements (p < 0.01 on five of the subscales: withdrawn, thought, attention, 
delinquent and aggression; p < 0.05 on two subscales: anxiety and social) were found on 
seven of the eight CBCL subscales. The participants also showed statistically significant 
improvements on the Youth Outcome Questionnaire, and the Young Mania Rating Scale. All 
effect sizes were relatively large at over 0.8 (Cohen’s d). No participants discontinued 
supplement use due to adverse effects; however, the two participants who were taking 
psychiatric medication experienced moderate excitation and agitation, but this was not 
reported by any of the children who were not taking psychiatric medication. The largest 
limitation of this study was the possible expectancy effect, as parents were the sole 
observational rater during the trial period and they were aware that their child was taking 
the supplement. The pervasive improvement on these multiple outcome measures and the 
magnitude of effect sizes however, strongly supports the value of further systematic efficacy 
research. 
 In the first study involving typical school children and the effects of a low dose 
vitamin-mineral supplement on violence and anti-social behaviour, Schoenthaler and Bier 
(2000) administered a Klaire Laboratory supplement, a low dose vitamin-mineral 
supplement for four months to 196 school students. The total number of participants was 
468. The participants were from two ‘working class’ primarily Hispanic schools aged 
between six and twelve. These participants were randomly assigned in a double-blind 
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fashion to either the placebo or supplement group. The supplement contained 50% of the 
U.S. RDA of a number of vitamins and minerals other than vitamin C which was increased to 
40 mg. The researchers aim in giving this supplement was to raise the vitamin-mineral 
intake of the participants to the levels recommended at the time by the National Academy 
of Science for children in this age group. There were 80 students who completed the trial 
and were disciplined during the time period. Half of these children were from the 
supplement group. These 40 disruptive school children from the supplement group were 
involved in 47% less serious rule violations during the four month trial period when 
compared to 40 similarly disruptive schoolchildren who were given placebos.  This group 
also had lower rates of eight types of recorded infractions, including threats/fighting, 
disorderly conduct and endangering others. Only one of the 40 children who received 
disciplinary action during the intervention period committed three or more offenses, while 
nine of the forty children taking the placebo tablets committed three or more offenses. 
Importantly, the 47% difference in anti-social behaviour between the supplement and 
placebo groups is accounted for by the presence of these nine habitual offenders in the 
placebo group. Correction of nutrient intake, usually corrects the low concentrations of 
vitamins in the blood and improves brain function, however deficiencies would not have 
been corrected with the placebo pills. Schoenthaler and Bier speculate that this is evidence 
that for the minority (habitual offenders), undiagnosed and untreated malnutrition is likely 
to have impaired their brain function to such an extent that normal learning from discipline 
did not occur.  A similar reduction in anti-social behaviours has also been found in adult and 
juvenile inmate populations (Gesch et al., 2002; Schoenthaler, 1985a; Wolfgang et al., 
1972), lending further weight to the role of nutrient intake correction in significantly 
reducing anti-social behaviour in both older incarcerated subjects with histories of antisocial 
behaviour and normal populations of younger disruptive children in an educational setting. 
 These results indicate that micronutrients are likely to be effective in moderating a 
number of mood or general behaviour variables including anxiety, mood or behavioural 
disorders, drastic mood changes, unpredictable behaviour, explosive outbursts and 
antisocial behaviours. Further testing is required to identify the specific areas within mood 
and behavioural disorders for which micronutrients are most effective, and the specific 
mixture of nutrients that are most effective at ameliorating mood and behavioural 
symptoms. 
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2.5. Cognition 
 Cognition appears to be the most common area of interest and conflict over 
mechanisms of action, in research investigating the effects of micronutrients for children. A 
common school of thought is that significant improvement in intelligence quotient (IQ) is 
only found in those children who were poorly nourished prior to supplement administration 
(Schoenthaler, & Bier 1999; Benton 2001), and that the large improvement in these few 
poorly nourished children, is responsible for the significantly greater IQ increases in 
treatment groups, for example found in Schoenthaler, et al. (2000) and Schoenthaler, et al. 
(1991). Micronutrient studies that investigated the effects of supplementation on cognition 
in children are outlined in the following section, including two studies that did not find 
significant cognitive improvements following micronutrient supplementation.  
Schoenthaler, et al. (1991) conducted a randomised placebo controlled trial with 
school children aged between 13 and 16, however only non-verbal IQ was measured. The 26 
delinquent participants were measured pre and post treatment on the Wechsler Intelligence 
Scale for Children-Revised (WISC-R). Those participants randomly assigned to the 
supplement group received a Klaire Laboratory supplement for the 3 month trial period. 
Following the trail period, significant increases were found in the non-verbal IQ (p<.001) of 
the supplement group. No significant non-verbal IQ change was found in the placebo group. 
This difference in IQ gain was found however, to be attributable to 4 of the 15 children who 
took the active micronutrient tablets. The remaining 11 supplement group participants were 
found to have an IQ change at post-test that was closely matched to that of the placebo 
group. Through examinations of pre-test nutrient status, the four respondents responsible 
for this group difference in IQ change, were found to have low water-soluble vitamin 
concentrations in their blood, this was not found in the remaining 11 respondents in the 
supplement group. Pre-test brain electrical activity mapping on six children with low 
concentrations of blood vitamins was conducted by a neurologist who was blinded to 
participant treatment status. Prior to the study all six children were found to have abnormal 
electroencephalographic (EEG) activity. The two children from the abnormal EEG group who 
received placebos demonstrated no improvement in EEG activity at post-test. The four who 
received the micronutrient supplement had markedly improved EEG activity, with a 
reduction of EEG activity abnormalities from 14 to 2. Schoenthaler et al.’s (1991) results 
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support the theory that gains in nonverbal IQ would be found among poorly nourished 
children.  
Schoenthaler et al. (2000) conducted a randomised double-blind, placebo controlled 
trial involving 245 Arizona school children aged 6 to 12 years. Children were randomly 
assigned into the supplement or placebo group, and pre-test screening showed the 
supplement and placebo groups had no significant differences in age, gender, race or pre-
test IQ score. The supplement, administered over 3 months, was a low dose micronutrient, 
which provided 50% of the U.S daily recommended allowance of vitamins and minerals. 
Post-test nonverbal IQ as measured by the WISC-R, found a 9.97 point IQ gain in the 
supplement group, and a 7.5 point IQ gain in the placebo group. The difference in IQ gain of 
2.47 points was found to be significant (p < 0.05). Further analysis revealed the gain could 
be contributed to a minority of children who produced IQ gains of over 15 IQ points. They 
attribute this large increase in IQ found in the minority of children, to poor nourishment 
before supplementation. 
A two-by-two factorial randomised placebo controlled, double blind trial was 
conducted to investigate the combined effects of micronutrients and essential fatty acids on 
cognition in school children (Osendarp et al. 2007). This study consisted of four participant 
groups: 1) received multivitamins; 2) received docosanhexanoic acid (DHA) and 
eicosapentaenoic (EPA); 3) received multivitamins, DHA and EPA; and4) received a placebo. 
The study was carried out over one year, with participants receiving their supplement or 
placebo 6 days a week. The participants were aged between 6 and 10 years of age, 396 from 
Adelaide, Australia and 384 from Jakarta, Indonesia. Pre-test bio-chemical analysis revealed 
Australian participants to be generally well nourished and the Indonesian participants to be 
in general under nourished. The micronutrient treatment groups in Australia were found at 
post-test measurement to have significant improvements in scores representing verbal 
learning and memory with an estimated effect size of 0.23 (95% CI: 0.01, 0.46). A similar 
trend although non-significant was found amongst the Indonesian girls, for whom the  
estimated effect size for the verbal learning and memory scores was 0.32 (CI: -0.01, 0.64). 
The addition of DHA and EPA to the multivitamin supplement was not found to result in 
beneficial effects on cognitive performance. This study suggests that supplementation with 
multiple micronutrients can result in improvements in verbal learning and memory in well-
nourished school children. This is contradictory to the previous findings of Schoenthaler, et 
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al. (2000 & 1991) of large improvements in IQ of under nourished children, and no 
significant IQ change in children who are well nourished following micronutrient 
supplementation. This clearly highlights the need for further research that uses 
micronutrient supplements with consistent compositions and the use of similar IQ 
measurement tools to clearly define the role of micronutrients in cognition. 
Benton and Cook (1991) used a Larkhall Laboratories supplement in their 
randomised double blind, placebo controlled study, which investigated the effects of six to 
eight weeks supplementation on a number of intelligence measures. The 47 participants 
were all six years of age. The post-test intelligence scores revealed an average 7.6 point 
increase in IQ in the supplement group, which was found to be a significant increase (p 
<.001). No significant change in IQ was found in the placebo group. After an examination of 
the subscales, it was found that the significant changes in IQ at post-test measurement for 
the supplement group were primarily on non-verbal measures. This finding is of theoretical 
importance when looking at how micronutrient supplementation may result in improved 
cognition. Verbal IQ tests are largely measures of crystallised ability and non-verbal IQ tests 
are measures of fluid ability (Cattell, 1943). Benton and Cook (1991) postulate that if poor 
diet was inhibiting and micronutrient supplementation was facilitating neurochemical 
efficiency, then as they found, it would be fluid intelligence that would be expected to be 
stimulated, which may be one way in which micronutrient supplements can lead to 
improved cognition. Post-test scores also revealed that the children who received 
supplements were more likely than the placebo group to concentrate on the task ( p <.05) 
and less likely to fidget (p<0.05). The researchers suggest that this may be evidence of 
micronutrient supplementation improving the mood of those with an inadequate diet. 
Indian researchers Kumar and Rajagopalan (2008) also investigated the effects of 
micronutrient supplementation on school children. The participants aged between 7 and 11 
years old were randomly assigned to either: 1) the control group, 72 participants; or 2) the 
micronutrient group, 51 participants. The experimental group consisted of school boarders 
only, and the micronutrient supplement was delivered in their food. Precautions and dose 
adjustments were made in order to protect the integrity of the micronutrient supplement 
cooked into the food for the experimental group participants. The school was chosen from a 
list of schools with the minimum number of intervening holidays, in order to limit the 
number of days where the children would go home, which would interrupt treatment. 
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Following one year of supplement administration, the mean improvement in five out of the 
seven memory and attention scores was found to be significantly greater in the 
experimental group than the mean change in the control group (p < .05). In the overall IQ 
score measured by Ravens progressive matrices, no significant improvements however were 
noted for either group. The haemoglobin, haematocrit and red blood cell count significantly 
improved in the experimental group following supplementation (p <.05). In contrast, a 
significant decline in haemoglobin and red blood cell count was discovered at post-test in 
the control group. Kumar and Rajagopalan link the IQ measurement findings and blood test 
results, suggesting that iron deficiency anaemia can be improved and that this can result in 
improved scores for children with lower scores on tests of cognition. This is a broad 
statement however, that needs further exploration. 
In a different approach to micronutrient enhancement of cognition, Sandstead, et 
al.’s (1998) interest was in the effects of zinc of cognition. They conducted a trial with 740 
urban low income Chinese children aged between six and nine years of age. Outcomes were 
measured at baseline and after the test period of 10 weeks. This trial had no placebo group. 
The three treatment groups consisted of: 1) received zinc; 2) received zinc and a 
micronutrient supplement; and 3) received a micronutrient supplement. The micronutrient 
supplement used in this trial was specifically created to best compliment the effects of zinc, 
for example the folate level was set at 25% of the RDA of the National Research Council 
(National Research Council, 1989), and the following minerals were excluded due to the 
possibility of interference with the intestinal absorption of zinc: iron, calcium, magnesium 
and phosphorus. Following treatment, which was administered six days a week for the 10 
week trial period, neuropsychological performance was measured by tasks from the 
Cognition-Psychomotor Assessment System-Revised (CPAS-R). Neuropsychological 
performance was associated with more overall improvement in the zinc plus micronutrient 
group than in the zinc or micronutrient groups. The significant differences between these 
groups (p <.05) were noted on measures of concept formation, abstract reasoning, and 
circular tracking (a measure of sustained attention). The significant improvements in 
neuropsychological performance found in the  participants who received zinc and a 
micronutrient supplement, suggest that zinc alone is not the most effective cognitive 
enhancer, and that the repletion of other micronutrients is also necessary when aiming to 
achieve significant improvements in cognitive performance. 
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Cognition can also improve in atypical child populations following micronutrient 
supplementation. Harrell et al. (1981) investigated the effect of eight months of 
micronutrient supplementation on 16 children with Down syndrome. Five of the children 
received the active supplement, which contained eight minerals in moderate amounts and 
11 vitamins in large amounts. The remaining 11 children received a placebo. The 
improvement in IQ at four months was found to be significantly greater in the supplement 
group compared to the placebo group (p<.05). The significant improvement in IQ was 
maintained in the supplement group after eight months supplementation, with results 
indicating a significant gain in IQ (p <.001). These findings indicate that micronutrient 
supplements may be useful when aiming to improve cognitive in a wide range of children. 
In contrast to the before mentioned cognition studies that found positive significant 
results as a result of micronutrient supplementation, Perlman, et al. (2010) and Nelson, et 
al. (1990) did not find significant improvements in cognition following supplementation. 
Perlman, et al. (2010) investigated the supplement effects in New Jersey, United States, of a 
low dose micronutrient supplement on grade point average change, late arrivals to school 
and school days absent. The study was randomised, double blind, and placebo controlled 
and contained 640 participants aged between 6 and 12 years old. The multivitamin 
administered in this study was designed to be equivalent to a standard over the counter 
multivitamin supplement. The ingredients and doses used in this supplement were not 
however, provided in the published research, and were not able to be obtained through 
attempted correspondence with the primary author. The micronutrient and placebo were 
administered on school days only. Post-test measurement revealed no significant 
differences in grade point average scores, the number of days absent from school or in 
lateness to school following four months of the micronutrient supplementation. There are a 
number of factors that may have led to this non-significant finding: the administration of the 
supplement exclusively on school days, the low dosage supplement used, the outcome 
measurements selected (school absenteeism and GPA scores), and the lack of measurement 
of non-verbal forms of IQ. 
Nelson, et al. (1990) investigated the effect of a specifically created micronutrient 
supplement on the verbal and non-verbal intelligence of typical British school children 
between the ages of 7 to 12 years old. The randomised, double blind, placebo controlled 
study consisted of 194 successful participant completers. The supplement or placebo was 
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administered by teachers during the week, and extra pills were given to the child to 
administer to themselves in the weekends. Following the 28 days treatment period, no 
significant differences were found between the experimental and control groups. The 
limited trial period and the dosages used in the micronutrient supplement may be partially 
responsible for the lack of effect found. The nutrients included in the supplement were 
broad, the dosages however, were in general lower than the dosages used in previous 
cognitive micronutrient research.  
The scientific literature indicates that micronutrient supplementation when used to 
improve the cognition of school children and possibly other a-typical child populations, may 
have a significant effect on a child’s cognitive functioning. The two cognitive studies with 
non-significant findings however, highlight the need for further investigation into the 
duration of administration necessary and the best method of measurement for cognitive 
change.  
 
2.6. Schizophrenia 
 One study was identified that examined the effect of a micronutrient supplement on 
the symptoms of schizophrenia. This study found symptom reductions resulting from 
supplementation. This study was a case report on a 17 year old, drug resistant schizophrenic 
and manic depressive girl. Weeks (2004) recommended dietary changes and administered a 
broad based micronutrient supplement specifically tailored to the patient’s needs. After 
taking the mixture of micronutrients for one month, the patient was completely off her 
medication and felt much better. Weeks (2004) theorised that many of the girl’s initial 
symptoms may have been exaggerated at the outset due to a medical overdose prescribed 
by her previous psychiatrist, so the symptom alleviation cannot be completely attributed to 
micronutrient use.  
This study provides preliminary indications that micronutrient supplements may be 
worth exploring further in the treatment of schizophrenia. 
 
Presented in the following section is a description of all of the ingredients included in 
the supplements in the above mentioned studies, as well as the ingredients included in 
commercial supplements. This is to provide a brief overview of the key roles and 
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characteristics of the wide spectrum of micronutrients included in the micronutrient 
supplements. 
3. Key Roles of Individual Micronutrients  
The nutrient reference values referred to in the following section include the 
Recommended Dietary Intake (RDI), Adequate Intake (AI), Upper Level of Intake (UL) and 
Lowest Observed Adverse Effect Level (LOAEL). The values presented unless stated 
otherwise are from national Health and Medical Research Council (NHMRC, 2006) designed 
to guide the public to optimal health and well–being. These guidelines take into account 
existing food cultures, cultural diversity, sustainability and cost. The RDI value is the dietary 
intake level sufficient to meet the nutrient requirements of nearly all healthy individuals. AI 
values are given when an RDI cannot be determined. An AI value is based on observed or 
experimentally determined estimations of nutrient intakes that are assumed to be 
adequate. Consequently, AI values can be interpreted with less confidence than RDI values. 
A UL value is the highest daily nutrient intake level likely to pose no adverse health effects 
to almost all individuals. Above the UL intake, the potential risk of adverse effects from 
excessive nutrient intake increases. Members of the general population are cautioned to 
not routinely exceed UL intakes. The LOAEL is the lowest exposure level at which there is 
statistically or biologically significant increases in the frequency or severity of adverse 
effects between the exposed population and the appropriate control group (NHMRC, 2006). 
 In the following sections the ingredients of micronutrient supplements are 
described. Firstly, vitamins are individually discussed. This discussion includes a description 
of essential roles of vitamins in both mental and physical health, and the New Zealand RDI 
or AI, UL and LOAEL vitamin dose, generally for children aged between 9 and 13 unless 
stated otherwise. Secondly, the minerals that appear in micronutrient supplements are 
described. The RDI, UL and LOAEL doses are presented in Table 1, along with the key 
physiological role of each mineral. Lastly, other ingredients including amino acids found in 
micronutrient supplements are presented in Table 2, along with a brief description of their 
key physiological or nutritional roles. 
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3.1. Vitamins 
Vitamin A is a fat soluble vitamin that plays an essential role in vision, the 
functioning of a healthy immune system and maintaining normal reproduction and growth.  
An adequate supply of vitamin A also helps prevent morbidity and mortality from infectious 
disease, particularly in children (Glasziou & Mackerras 1993). Vitamin A can come in a 
number of forms including retinol, retinal, retionoic acid or retinol ester.  Vitamin A 
deficiency, specifically retinoic acid and retinal forms of vitamin A, can result in abnormal 
dark adaptation, xerophthalmia (a serious eye disorder) or blindness.  This is uncommon in 
New Zealand; however the New Zealand Children’s Survey 2002 (Ministry of Health 2003) 
stated that a significant proportion of Pacific children might be at risk of insufficient intakes 
of vitamin A. The RDI for children aged between 9 and 13 years is 600 µg. The UL for vitamin 
A as retinol is 1,700µg daily for children aged between 9 and 13. The UL for beta carotene 
cannot be established for supplement use as no dose-response relationship for the 
observed effects is available (European Commission, 2000). 
Thiamin (vitamin B1) is a water soluble substance that is essential for converting 
blood sugar into energy. If intake of thiamin is high, only a small amount will be absorbed 
with the rest being excreted via urine, with the total body content of the vitamin being 
around 30mg. Thiamin is also involved in metabolic activities in nerves, heart, and muscles 
and in the production of red blood cells. There are two major diseases that can result from 
thiamin deficiency, beri beri and Wernicke- Korsakoff syndrome. In western countries beri 
beri is seen rarely, with occasional cases found in alcoholics. Wernicke- Korsakoff syndrome 
is usually found in people with chronic alcoholism who eat very little, as alcohol requires 
thiamin for its metabolism. This syndrome is associated with severe psychiatric and 
cognitive symptoms (Mann, 2000).The symptoms of Wernicke’s include confusion, lowered 
level of consciousness and ataxia. Studies where participants have been deprived of thiamin 
have found a range of outcomes including marked irritability, depression, fearfulness, 
emotional instability, anxiousness and lower mood (Graham, 2001; Benton 1995; Heseker 
1992). The RDI of thiamin for children aged between 9 and 13 years old is 0.9mg. The UL 
cannot be estimated due to insufficient data, although existing evidence available suggests 
that current intake levels of thiamin from all sources do not represent a health risk to the 
general population (Australia and New Zealand Ministry of Health 2006). 
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Riboflavin (vitamin B2) is a water soluble vitamin. The bioactive forms of riboflavin 
are key in the reactions in the catabolism of fuel molecules. It is also important in the body’s 
handling of nutrients including vitamin B₆ and the conversion of tryptophan to niacin. 
Deficiency can indirectly lead to increased cardiovascular risk, and may contribute to 
anaemia when iron levels are low (Powers 2003). Riboflavin deficiency can also lead to 
eczema, cracked skin, a burning sensation on the tongue and eye irritation. The RDI for 
children aged between 9 and 13 is 0.9mg daily. The UL for riboflavin cannot be estimated as 
no adverse effects have been associated with consumption in food or supplements, and 
those studies that have been undertaken with large doses did not systematically assess 
adverse events (Schoenen et al. 1998). 
Niacin (vitamin B3) plays a role in the intracellular respirations system and with 
enzymes involved in oxidation of fuel substrates. Essentially due to its role in energy 
metabolism the amount of niacin required is related to individual energy requirements. 
Niacin is a vasodilator, this means that it acts to widen blood vessels therefore increasing 
blood flow. A deficiency in niacin can result in the disease pellagra, associated with 
inflammation of the skin, diarrhoea, depression, thinning of the hair and in severe cases, 
delirium. Malnourished persons are at risk for developing niacin deficiency. The RDI for 
children aged between 9 and 13 years of age is 12mg daily. The UL of intake for niacin is 
important as even mildly high doses can cause a number of side effects including hot 
flushes, headaches, itchiness and stomach problems. The UL for children and adolescents 
aged between 9 and 13 for nicotinic acid is 20mg daily based on a body weight basis. The UL 
set for the same age group for nicotinamide intake is 500mg daily. This upper limit is set 
much higher as nicotinamide is not a vasodilator and therefore does not cause flushing. 
Pantothenic Acid (vitamin B5) is a component of coenzyme (CoA) and 
phosphopantetheine, and its role is important for the metabolism of fats, carbohydrates 
and proteins. CoA also plays an important role in the production of steroid hormones and 
the synthesis of vitamin A and D, and neurotransmitters. CoA is often combined with choline 
to produce acetylcholine, a neurotransmitter with important roles in memory, attention and 
cognitive functions. A deficiency in pantothenic acid would include symptoms such as 
abdominal distress, burning sensation in the feet, fatigue, sleep disturbance and insulin 
sensitivity however B₅ deficiency is not common. The AI for pantothenic acid for children 
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aged between 9 and 13 years of age is: 5mg daily for boys and 4mg daily for girls. The UL 
cannot be determined at this stage, but current intakes are unlikely to be associated with 
adverse health effects, as there are no adverse effects of oral pantothenic acid in either 
humans or animals (Wellington: Ministry of Health, 2011). 
Vitamin B6 comprises six compounds: pyridoxal, pyridoxine, pyridoxamine and their 
respective 5’ phosphates. Vitamin B6 acts as a coenzyme in the synthesis of a number of 
neurotransmitters derived from amino acids including serotonin, dopamine, acetylcholine, 
norepinephrine and GABA. It is also required for carbohydrate metabolism and other 
aspects of amino acid metabolism (Mann, 2000). Clinical deficiency is rare, however 
symptoms can include depression, irritability and confusion (Hawkins & Barsky 1948; Leklem 
1991). Hvas (2004) found that lower levels of pyridoxal phosphate were significantly 
correlated with higher levels of depression. Deficiency can also lead to skin problems and 
microcytic anaemia. The RDI of vitamin B6 for children aged between 9 and 13 is 1mg. The 
UL of intake for vitamin B6 as pyridoxine is 30mg daily for children aged between 9 and 13. 
Biotin (vitamin B7 or vitamin H) is involved in the production of amino acid proteins 
and fatty acids, as it is a cofactor for four carboxylase enzymes. Biotin deficiency is rare; 
however, it can lead to withdrawn behaviour, a delay in cognitive development or 
hallucinations (Gaby 2006). The evidence regarding biotin requirements was deemed 
insufficient to set an RDI, therefore an AI of 20µg daily for children between the ages of 9 
and 13 was set. There was also insufficient evidence of adverse effects to set a UL. 
Preliminary research has suggested that high doses may cause weakened immune 
responses (Zempleni et al. 2001). 
Folate (vitamin B9) occurs naturally in a number of foods but is less stable and bio-
available than its man-made counterpart folic acid. The bioavailability of folate in foods is 
around 50% to 60%, compared to folic acid which when used as a supplement on an empty 
stomach is almost 100% bio-available. Folate (or folic acid) is vital in a number of metabolic 
processes. Key roles include their role in the metabolism of amino acids and the production 
of proteins. It is also used in the manufacturing of neurotransmitters, and for the synthesis 
of genetic materials or DNA in cells, without folate living cells could not divide. As it is a 
cofactor in the synthesis of serotonin its role is vital in helping to maintain normal serotonin 
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levels. Depression is a common symptom of folate deficiency (Alpert, 1997). Megaloblastic 
anaemia and macrocytosis can also result from more severe cases of folate deficiency 
(Mischoulon 2000). The RDI for children aged between 9 and 13 is 300µg. The UL for dietary 
supplemental folic acid is not able to be established; however the UL for dietary folate is 
600µg daily for children aged between 9 and 13. The LOAEL was set at 5mg daily. 
Vitamin B12 has the biological activity of cyanocobalamin in micronutrients. This 
water soluble vitamin is required for the synthesis of fatty acids in myelin, and for the 
manufacturing of genetic material.  Adequate intakes are also necessary for normal blood 
function and healthy functioning of the nervous system. Children who are deficient in B12 
may experience growth failure. Deficiency can also lead to neurological symptoms, such as 
numbness, tingling of extremities, or blood related symptoms including lowered energy, 
shortness of breath and fatigue. Cognitive functioning can also be adversely affected from 
the age of adolescence (Louwman et al 2000).  A major concern resulting from B12 
deficiencies is elevated homocysteine, a possible risk factor for heart disease and 
Alzheimer’s disease. Several studies have found that depressive patients with psychosis 
symptoms often had lower B12 levels than depressive patients with no psychosis symptoms 
(Bell 1991, Bell 1990). The RDI for children aged between 9 and 13 years old is 1.8µg. Vegan 
children would be at a high risk for vitamin B12 deficiency as the only natural dietary sources 
are in animal products. The UK Expert Group on Vitamins and Minerals (2002) states that it 
is not possible to establish a UL as there is insufficient data. There have been no adverse 
effects reported in association with excess B12 intake from food or supplements in healthy 
individuals. This apparent lack of toxicity could relate to the body’s ability to decrease 
absorption in response to high intakes. 
Choline is essential for foetal brain development and is a precursor for a number of 
compounds including the neurotransmitter acetylcholine. Evidence suggests that at all ages 
choline may improve cognitive function, learning and memory. Choline deficiency has been 
found to be related to poor cognitive performance (Fioravanti & Yanagi 2004). Although 
essential in the diet, choline deficiency appears not to occur in the general population; 
however, the Australia and New Zealand Ministry of Health (2006) guidelines state that 
consideration of choline intake needs to be further explored. The AI for children aged 
between nine and thirteen is 375mg daily, although animal studies suggest that females 
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may require less choline than males (Tessitore et al 1995). The UL for the same age group is 
1,000mg daily, based on studies that reported cholinergic effects and body odour effects 
after large choline doses. The LOAEL was set at 7.5g daily. 
Vitiamin C is water soluble and is an antioxidant necessary for normal growth and 
development. In humans it has been proven to protect lipids in plasma against oxidative 
damage (Frei 1991). It aids in the absorption of iron and copper (Hallberg 1985), the 
stabilisation of folate (Stokes et al 1975), and the sparing of alpha-tocopherol (Halpner et al 
1998). Vitamin C is necessary for the growth and repair of tissues in all parts of the body, the 
body however does not naturally produce or store the vitamin. Consequently, maintaining a 
balance of vitamin C rich foods in the diet is important. A deficiency in vitamin C can cause 
scurvy, the symptoms of which can ultimately lead to death. In adults the clinical signs of 
scurvy begin to occur at intakes of 7-8 mg or less per day (Goldsmith 1961). The method of 
intake is also important. Absorption is better when, for example, 250mg is taken four times 
daily, rather than 1,000mg taken once daily. The RDI for children aged between 9 and 11 
years of age is 40mg. The UK Expert Group on Vitamins and Minerals (2002) states that it is 
not possible to establish a UL for vitamin C, but sets 1,000 mg daily as a prudent limit. The 
LOAEL has been identified at 3,000 to 4,000 mg daily by Cameron and Campbell (1974). 
Vitamin D is available in two forms, D2 (ergocalciferol) and D3 (cholecalciferol), both 
of which are used in micronutrient supplements. In the natural world, D3 is produced by the 
action of sunlight on the skin, and D2 is found in a limited range of foods. At nutritional 
doses these two forms of vitamin D appear equivalent; however at high doses D2 is slightly 
less potent. Vitamin D3 is preferable to D2 as it 20-40% as effective as D3 in maintaining 
serum concentrations of 25-hydroxy vitamin D. In the general population, vitamin D status is 
maintained through exposure to sunlight, and for this reason deficiency is more likely to 
occur during the winter months (Holick 1995). Vitamin D is vital to bone formation and 
maintenance. Research also indicates that vitamin D3 has an important role in the 
functioning of the central nervous system (Garcion 2002). Abnormally low levels of vitamin 
D have also been found in patients with schizophrenia, depression, and alcoholism 
compared to healthy controls (Schneider 2000). In children, a deficiency in vitamin D can 
result in rickets, which leads to bowed legs and knocked knees. The AI for children aged 
between 9 and 13 years old 5µg vitamin D daily. Importantly, it should be taken into 
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consideration that children and adolescents with marginal calcium intakes may have an 
increased need for vitamin D (Australia and New Zealand Ministry of Health 2006). The 
Adult Nutrition Survey 2008/09 aimed at New Zealanders 15 years of age and above, found 
that around 5% of adults in New Zealand are deficient in vitamin D and a further 27% are 
below the recommended blood level of vitamin D (Wellington: Ministry of Health, 2011). 
The UL is 80µg daily for children aged nine to thirteen years, as there is little available data 
for children and adolescents on dose response, the UL recommendation for adults was 
applied. 
Inositol is an isomer of glucose, which has been found to be useful in a number of 
psychiatric disorders, including significant benefits in the treatment of panic disorder, 
depression, obsessive compulsive disorder and bulimia (Gaby 2006). In one study, significant 
differences in levels of intracellular inositol were isolated in the brains of children with 
ADHD when compared to controls (Moore et al 2006). Inositol serves several important 
functions in the body, comprising part of all cell membranes, contributing to the function of 
nerves and muscles, and helping the liver process fats. The Australia and New Zealand 
Ministry of Health Nutrition Guidelines (2006) did not set daily dosage recommendations for 
inositol, and it appears that no human long-term safety studies on inositol have been 
conducted. 
Vitamin E sourced naturally is called d-alpha-tocopherol; the synthetically produced 
form is dl-alpha-tocopherol. Vitamin E is a fat soluble antioxidant that helps prevent cell 
membrane damage. An AI dosage of α-tocopherol equivalents was set for males aged 
between 9 and 13 at 9mg daily. The AI dosage set for females aged between 9 and 13 years 
of age was 8mg daily. There have been a number of studies using supplementation of 
vitamin E with d- α – Tes ranging from 540mg up to 970mg a day, and other than some 
minor effects, adverse events have been rare.  The UL for vitamin E as α-tocopherol 
equivalents was set at 180mg daily for children aged between 9 and 13. Larger doses above 
1,000mg daily may cause bleeding problems, particularly in people taking anti-clotting 
medications (Sesso et al., 2008). 
Vitamin K is vital for its role in blood clotting and prevention of bleeding. Deficiency 
can cause bleeding tendency. As a series of essential fat-soluble compounds, vitamin K is 
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needed for the chemical modification of a group of proteins with calcium-binding 
properties, consequently vitamin K contributes to maintaining healthy bones and healing 
fractures. The AI dosage for children aged between 9 and 13 years of age is 45µg daily. No 
ULs were set for vitamin K as no adverse effects have been found in animals or humans. 
The following sections outline the minerals, amino acids and other ingredients found 
in micronutrient supplements. Presented in Table 1, are the mineral ingredients in 
micronutrients products and the amount of each of these minerals needed in a New Zealand 
child’s daily diet, this is indicated in the RDI column.  In Table 2, is an outline of the basic 
physiological or nutritional roles of other ingredients found in micronutrient supplements. 
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3.2.Minerals 
 
Table 1 
Micronutrient Supplement Minerals 
Australia and New Zealand¹ Recommended Daily Intakes (RDI), Upper Intakes (UL), LOAEL, and Key Physiological Roles 
Mineral *RDI **UL LOAEL Key Physiological Roles 
Boys Girls    
Boron Not Set Not Set   A component in building strong bones, treating osteoarthritis and 
building muscle. 
Calcium 1000 mg 1000 mg 2, 500 mg  Necessary for the normal development and maintenance of bones, 
and the proper functioning of neuromuscular and cardiac function. 
Copper 1.3 mg 1.1 mg 5 mg  Deficiency results in defects in connective tissue that leads to 
vascular, skeletal and anaemia problems. Deficiency can also result 
in immune and cardiovascular problems especially in infants. 
Iron 8 mg 8 mg 40 mg 70 mg Iron deficiency is a common nutritional problem in industrialised 
countries, and in developing countries it is a leading cause of 
impairment of normal mental development of infants. Iron is an 
especially important component of haemoglobin which is 
important in transferring oxygen to tissues. It is also integral to the 
working of various tissues through the role it plays in enzymatic 
reactions. Deficiency can result in reduced physical work capacity, 
delayed psychomotor development in infants, impaired cognitive 
function and immunity, and adverse pregnancy outcomes.  
Iodine 120 µg 120 µg 600 µg 1,700 µg Required for normal growth and development of tissues, 
especially in the brain development of the developing foetus. Also 
important in energy production and oxygen consumption, 
therefore helping maintain the bodies metabolic rate. Iodine is 
also vital in the production of hormones. A recent study involving 
40 
 
184 New Zealand school aged children found iodine 
supplementation resulted in significantly improved performance in 
tests of perceptual  reasoning, a high level of intellectual function 
(Gordon et al 2009). Great progress was made in food fortification 
with the iodisation of salt, greatly reducing the number of 
countries where iodine deficiency was a public health concern. A 
2006 study conducted on Australian children aged eight to ten 
years old, found that almost half of Australian children were iodine 
deficient (Li et al 2006). 
Magnesium 240 mg 240 mg 350 mg 360 mg Is a cofactor in more than 300 enzyme systems. It is involved in 
both aerobic and anaerobic energy generation and in glycolysis.  It 
is also required for mitochondria to carry out oxidative 
phosphorylation. Magnesium plays a role in post-synaptic receptor 
function and has a depressive effect at synapses, inhibiting the 
release of neurotransmitters, such as acetylcholine, and 
antagonising receptors such as the NMDA receptor. Magnesium 
deficiency can cause depression, behaviour and personality 
changes, apathy, irritability and anxiety (Wacker 1968, Rasmussen 
1989). An animal study involving magnesium deficiency induced in 
cows found deficiency to be associated with reduced dopamine 
levels in the cerebral cortex and cerebellum and lower 
noreinephrine in the corpus striatum (McCoy 2000). 
Manganese 3 mg 2.5 mg None set  Essential to the formation of bone. Is also involved in the 
metabolism of carbohydrates, cholesterol and amino acids. 
Molybdenum 34 µg 34 µg 1, 100 µg  Acts as a cofactor for a number of enzymes. 
Nickel     Nickel sensitivity can cause dermatitis and is one of the most 
common causes of contact dermatitis. High intakes are dangerous. 
Phosphorous 1, 250 
mg 
1, 250 mg 4, 000 mg NOAEL 
10,000 
mg daily 
As phosphate is a major buffer of acid in urine and helps protect 
blood systemic acid balance. It also acts as a temporary store and 
transport mechanism for energy. Phosphorus plays a critical role in 
blood and extracellular fluids. Deficiency results in symptoms 
including anorexia, anaemia, muscle weakness, bone pain, rickets, 
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confusion and muscle weakness. 
Potassium AI = 3, 
000 mg 
AI = 2, 
500 mg 
None set  A major part of intracellular fluid and a component of lean body 
tissues. 
Selenium 50 µg 50 µg 280 µg  Functions as an antioxidant and thyroid metabolism.  Selenium is 
used for diseases of the heart and blood vessels, including stroke 
and hardening of the arteries. Selenium may also help improve 
mood and general feelings of well-being in people with thyroiditis. 
Due to low soil selenium levels dietary intakes of selenium are 
lower in New Zealand than many other countries (Thompson 
2004a). Organic selenium can almost completely be absorbed by 
the body, however inorganic selenium absorption is variable, 
generally around 50%. 
Silicon Not Set Not Set   Orthosilicic acid is the form predominantly absorbed. Deficiency 
induces deformities in skull and peripheral bones, poorly formed 
joints, reduced contents of cartilage, collagen, and disruption of 
mineral balance in the femur and vertebrae (Martin 2007). 
Sulphur Not Set Not Set   Is a key constituent of numerous nutrients including biotin and 
thiamin. Cysteine and methionine, two of the body’s sulphur 
containing amino acids, have powerful antioxidant properties and 
help control the absorption of heavy metals, such as lead. 
Vanadium Not Set Not Set   Vanadium's primary mode of action is as a cofactor that enhances 
or inhibits enzymes. It has potential to play a role in the building 
material of bones and teeth, and in the treatment of diabetes 
(Badmaev et al 1999). Before it can be helpful in pharmacological 
doses the gastro side effects from of vanadium must be reduced. 
Zinc 6 mg 6 mg  25 mg 60 mg Helps maintain the structural integrity of proteins and regulate 
gene expression. Mild deficiency can lead to impaired growth 
velocity, suboptimal pregnancy outcomes and impaired immune 
responses. Severe deficiency can also result in alopecia, diarrhoea, 
delayed sexual development and impotency, eye and skin lesions 
and impaired appetite. Psychological consequences of zinc 
deficiency include behavioural disturbances, depression and 
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mental confusion (Mann, 2000). Lower zinc levels have been found 
to correlate with increased depression severity within major 
depression populations (Maes 1994). 
Notes:  
*Based on a child aged between 9-11 years old or 9- 13 years old. 
** Based on children and adolescents aged between 9 – 13 years old. 
¹ NHMRC. (2006). Nutrient reference Values for Australia and New Zealand including Recommended Dietary 
Intakes. Canberra, Australia. 
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3.3. Other vitamins and amino acids 
Table 2 
Other Micronutrient Supplement Ingredients 
Ingredient Key Physiological/Nutritional Roles 
Betanine Natural Dye 
Saccharin Artificial sweetener 
Sodium Cyclamate Artificial sweetener banned in the U.S. 
Sodium Bicarbonate Can be used as an antacid 
Sodium An essential nutrient that regulates blood 
volume, blood pressure, osmotic equilibrium 
and pH. 
Spirulina A complete protein containing all essential 
amino acids. It also contains in very small 
amounts vitamins B1, B2 , B3, B6, B9, vitamin C, 
vitamin D, vitamin A and vitamin E. It is also a 
source of potassium, calcium, chromium, 
copper, iron, magnesium, manganese, 
phosphorus, selenium, sodium and zinc. 
Taurine An amino acid that supports neurological 
development and helps regulate the level of 
water and mineral salts in the blood. It is also 
thought to have antioxidant properties. 
Lecithin Lecithin is a lipid that consists mostly of choline. 
It helps to prevent arteriosclerosis, protects 
against cardiovascular disease, improves brain 
function, helps keep the liver and kidneys 
healthy, aids in thiamin and vitamin A 
absorption. 
Isomalt Natural sugar substitute 
Ashwagandha root Helps to boost the immune system and alleviate 
stress. The herb is also used to treat 
inflammation, improve memory and provides a 
rich source of antioxidants.  
 
Burdock root The beneficial effects of this herb include 
increasing circulation to the skin, helping to 
detoxify the epidermal tissues. 
Astragalus root Contains antioxidants. It is used to protect and 
support the immune system, and has anti-
inflammatory properties. 
Sarsaparilla root  A few reports suggest that sarsaparilla has both 
anti-inflammatory and liver-protecting effects. 
Fennel seed This herb is rich in potassium - an essential 
mineral. It is also useful for treating bloating. 
Ginko leaf Has been shown to be moderately effective in 
improving cognition in dementia patients. Also 
the treatment of the effects of mild to 
moderate cerebrovascular insufficiency as well 
as the effects of peripheral arterial occlusive 
diseases. 
44 
 
Gotu kola leaf Small herbal plant. Thought to aid wound 
healing. A mild adaptogen. 
Gymnema sylvestre leaf Thought to help in the treatment of diabetes. 
Milk thistle seed Supports optimal liver function.  
Schisandra fruit Is used for treating liver disease (hepatitis) and 
protecting the liver from poisons. Is also used as 
an adaptogen for increasing resistance to 
disease and stress. 
Slippery elm bark Contains antioxidants that help relieve 
inflammatory bowel conditions. Slippery elm 
also causes reflux stimulation of nerve endings 
in the gastrointestinal tract leading to increased 
mucus secretion. The increased mucus 
production may protect the gastrointestinal 
tract against ulcers and excess acidity. 
Mannitol May be useful clinically both as a diuretic and as 
an obligate extracellular solute. 
Lactobacillus acidophilus When included with a blend of other bacteria 
strains decreased the incidence of paediatric 
diarrhoea. It has been shown to improve bowel 
regularity. 
Rose Hips Contain a lot of vitamin C when fresh, but this is 
decreased substantially when dried and 
processed. Rose hips are also used for treating 
symptoms of stomach disorders. 
Fructose Fruit sugar found in many plants. 
Sugar Alcohol Hydrogenated form of carbohydrate, often used 
in place of sucrose. 
Sugar/ sucrose /glucose Sweetener 
Dextrose Glucose 
Tapioca Syrup Natural Sweetener 
Citric Acid Weak organic acid 
Malic Acid Known for its ability to increase energy and 
tolerance to exercise. This is because it is an 
essential component in the Krebs cycle, which is 
how our bodies convert food into energy.  
Vegetable Cellulose The dietary fibre that cellulose provides helps 
prevent constipation. 
Xanthan Gum Food additive 
Silica A mined mineral used as a flow agent and as a 
source of silicon. 
Vegetable Magnesium Stearate Its lubricating properties allow powders to flow 
freely through encapsulation machines without 
sticking. 
Vegetable Stearic Acid Often used as a filler in the manufacturing of 
drug or dietary supplement capsules.  
Corn Starch Thickening agent 
Carrageenan A family of linear sulfated polysaccharides that 
are extracted from red seaweeds. Studies 
suggest it might function as a topical 
microbicide. 
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Propylene Glycol Alginate An emulsifier, stabilizer, and thickener used in 
food products. 
Luo Han Guo fruit extract Natural sweetener 
Vegetable Stearin A wax derived from vegetable sources used as a 
lubricant in tablet compressing. 
Saccharides Sugars 
Acesulfame K Sweetener 
Strawberry Powder An antioxidant. 
Pectin Used as a gelling agent, thickening agent and 
stabilizer in food. 
Sodium Citrate A sodium salt that occurs naturally in the body. 
It is known as a buffer, meaning it can absorb 
hydrogen ions from acids and prevent large 
changes in the pH of solutions. This buffering 
capacity can help food and solutions remain 
stable over time. Additionally, buffers, such as 
sodium citrate, play critical roles in maintaining 
proper physiological conditions in body fluids, 
such as blood. 
Sunflower Oil High in vitamin E and low in saturated fat. 
Cane Juice Natural Sugar 
Tableting Aids A food grade substance that is added to a 
dietary supplement to constitute the form in 
which that supplement is sold; and includes an 
encapsulating aid. 
Carnauba wax Plant derived coating. 
Mangosteen Fruit Rich in antioxidants 
Cranberry fruit Raw cranberries have moderate levels 
of vitamin C, dietary fibre and manganese. Are 
of possible benefit to the cardiovascular 
system and immune system 
Broccoli Includes vitamin C, vitamin A (mostly as beta-
carotene), folic acid, calcium, and fibre. 
Spinach  Contains vitamin K and vitamin A, manganese, 
folate, magnesium and provides dietary fibre. 
 
Asparagus Stems Has a good level of dietary fibre. Fresh 
asparagus are rich in folates. Fresh asparagus 
also contains fair amounts of anti-oxidant 
vitamins such as vitamin-C, vitamin-A and 
vitamin-E and vitamin K. 
Carrot Root Are an exceptionally rich source of carotenes 
and vitamin-A. Beta carotene is one of the 
powerful natural anti-oxidant helps protect 
body from harmful fee radical injury.  In 
addition, it also has all the functions of vitamin 
A such as vision, reproduction (sperm 
production), maintenance of epithelial integrity, 
growth and development. 
Tomato Fruit Contains Lycopene. Lycopene is a vital anti-
oxidant that helps in the fight against cancerous 
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cell formation as well as other kinds of health 
complications and diseases. 
Acai Fruit Contains calcium, vitamin A, aspartic acid and 
glutamic acid.  
Pomegranate Fruit High in vitamin C and polyphenols, both 
substances which act as antioxidants and are 
naturally high in fibre. 
 
Grape seed Contains protein, lipids, carbohydrates and 
polyphenols. Acts as an antioxidant. 
Germanium Sequioxide There are two general forms of germanium: 
organogermanium compounds, which are 
carbon-containing compounds and inorganic 
geranium. This may have an anticancer effect. 
Alpha lipoic Acid Is one of the good fatty acids produced in every 
one of our cells. It is also an antioxidant. 
Glutathione Is a potent antioxidant. 
Garlic extract Garlic has been found to enhance thiamin 
absorption. Garlic is also a vasodilator. 
Lactoferrin Is a multifunctional protein, and one of the 
components of the immune system of the body 
Silymarin Is derived from milk thistle. Proved to be 
successful in treating alcohol-related liver 
disease. 
Royal bee jelly Is a source of biopterin 
Bilberry extract Is beneficial for eye health. 
Soy constituents Can lower plasma levels of low-density 
lipoprotein (LDL) and cholesterol. 
Dandelion The scientific name is taraxacum officinale. It is 
used as a diuretic, a mild appetite stimulant and 
to improve upset stomach. 
Echinacea  Supports the immune system. 
Pineapple Fruit Is a rich source of soluble and insoluble dietary 
fibre such as pectin. 
Apple Fruit Rich in dietary fibre. It contains good quantities 
of vitamin C and beta-carotene. They are also 
are rich in antioxidant phyto-nutrients 
flavonoids and polyphenols. 
 
3.4. Nutrients Summary 
There are a large number of ingredients included in micronutrient supplements. These 
ingredients play a wide variety of roles. Some of these ingredients appear to be included in 
supplements to ease pill consumption, to aid in the binding of supplement ingredients, to act as a 
sweetener, or to flavour the supplement. Other ingredients may play a number of mental or 
physical health roles. The combination of these ingredients may lead to varied or additive effects, 
not seen when nutrients are given on their own. 
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4. The New Zealand Context 
In 2006, a nationally representative sample of the New Zealand population completed the 
New Zealand Mental Health survey (Oakley-Browne, Wells and Scott, 2006). The prevalence of any 
mental health disorders in the previous 12 months in young people between the ages of 16 and 24 
identified by this survey was 28.6% (95% CI: 25.1, 32.3). The prevalence of a serious disorder for 
this population was 7.2% (95% CI: 5.7, 9.0). For both male and female New Zealanders the rates of 
depression have been found to be increasing with each birth cohort and the age of onset is 
lowering (Joyce et al. 1990). The importance of finding the most effective treatments increases 
with the increasing mental health prevalence represented in the New Zealand population and in 
particular with the decreasing age of disorder onset. In New Zealand, the highest prevalence of 
any mental health disorder is in Maori and Pacific people when compared with any other ethnic 
group (Oakley-Browne et al., 2006). Disorder prevalence’s are also higher for people who are 
disadvantaged either in education or household income (Oakley-Browne et al., 2006).  
There is an indication that New Zealand children attending primary or secondary medical 
care have a high useage of complementary and alternative medicine (CAM). In a sample of 100 
Christchurch children in primary or secondary medical care under the age of 12, Wilson, Dowson 
and Mangin (2007) found that the overall CAM-use was 70%. This prevalence rate is higher than 
that found in similar populations in Australia and Wales where prevalence was reported at 51% 
(Nicholson, 2006) and 41% (Armishaw & Grant, 1999) in Australia and Wales respectively. Of note, 
was that the children and parents in the Wilson, Dowson and Mangin (2007) survey were largely of 
New Zealand European ethnicity (87% and 90% respectively) and therefore may not be 
representative of all regional populations in New Zealand.  
Participants reported the use of 35 different CAM types. The two most common CAM 
treatments were arnica (43%) and multivitamins (17%). It was reported by the parents that CAM 
was predominantly as used for the prevention and treatment of acute or short-term symptoms. A 
valuable predictor of CAM use was found to be parents who use CAM treatments themselves. 
Children of parents who use CAM were found to be four times more likely to use CAM than those 
children whose parents do not use CAM. Higher education of the participating parent was also 
found to be strongly correlated with child CAM use. The results found by Wilson, et al. (2007) 
suggest that a large number of New Zealand parents use a variety of types of CAM in order to 
prevent or treat short term illnesses in their child receiving primary or secondary medical care. The 
higher rate of use among this Christchurch sample compared to the use in other countries could 
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mean that overall use of CAM in New Zealand children is higher. It may also indicate that 
micronutrient use is higher than international prevalence rates. The prevalence use of 
micronutrients will be explored in this research’s survey. 
5. The Current Investigation: Aims and Hypotheses 
It is the aim of this study to investigate whether the micronutrient supplements found to 
be effective in research, have ingredients or dosages comparable to micronutrients for children 
that are available over the counter. The ingredients and dosages for micronutrient supplements 
used in psychologically based studies that focus on children, will be found in a literature search of 
papers published internationally. The ingredients and dosage’s used in commercial products will 
be found from a broad array of micronutrient supplement brands available over the counter in 
New Zealand. The commercial micronutrient sample will be drawn from New Zealand 
supermarkets, health food stores and pharmacies, and a small sample will be included from 
supplements available over the counter in the U.S., Australia and England. It may be helpful to 
both consumers and practitioners to identify one or more New Zealand in-store micronutrient 
supplement that fits the effective research dosage and ingredient parameters. The comparison of 
the commercial and research micronutrient supplements may provide information to 
micronutrient users as to the likely efficacy of the in-store products on the psychological, cognitive 
and mood symptoms of their child. 
The aim of the on-line survey is to identify the key motivations of New Zealand parents 
when purchasing a micronutrient supplement for their child. In the survey the use of 
micronutrients given to New Zealand children is explored through questions that investigate: the 
most popular NZ micronutrient brands, demographic information about the parent, whether 
parents follow the recommended dosage when giving the supplement to their child, whether 
parents give any other dietary supplements to their child, parent’s strongest motivating factors in 
purchasing a micronutrient supplement for their child, the factors that influence their choice of 
micronutrient brand, and any perceived benefits that the parent attributes to micronutrient use. It 
is hypothesised that New Zealand parents will not be aware of the benefits of micronutrients for 
psychological symptoms, cognition and mood, and consequently will not purchase micronutrients 
for these purposes.  
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Method 
1. Study 1: Micronutrient Supplement Investigation 
1.1. Micronutrient Products 
A micronutrient supplement was defined as any product that labelled itself as a ‘multi-
nutrient, multivitamin and, or, multi-mineral, or micronutrient supplement’ and included three or 
more vitamins and/or minerals and/or amino acids.  Research products were defined as a 
micronutrient supplement tested on children and used in a psychologically focussed, 
micronutrient study. The products EMPowerplus and Spectrum Support are high end products 
available to purchase direct from the supplier on the internet. These products however, were 
classified as research products as they have both been tested in micronutrient research and 
cannot be brought in stores or from on-line pharmacies. Commercial products selected for 
comparison included at least one micronutrient product for children from each of the 
micronutrient brands that were available in New Zealand at the time of the search (December 
2011). The commercial products were found over the counter in supermarkets, health stores, and 
pharmacies, and on New Zealand based pharmaceutical internet sites. The commercial products 
also include a random selection of micronutrient supplements for children, that are available over 
the counter or on pharmaceutical internet sites based in Australia, America and the United 
Kingdom. 
In order to identify the average micronutrient composition of an effective supplement the 
papers included in the ingredient analysis were limited to those that found a significant effect in 
symptom reduction following micronutrient treatment. There were two papers that fit this 
criterion that were not included in the analysis as the ingredients and dosages of the supplements 
used were not supplied. The first of these two papers was Katz et al. (2010) which found a 
significant improvement in ADHD symptoms following broad base micronutrient supplement 
administration. The second of these papers was Weeks (2004), who found significant reductions in 
the abnormal characteristics of downs syndrome following supplementation. A further three 
papers which are outlined in Table 3, were not included in the analysis as they did not find 
significant symptom reductions as a result of micronutrient supplementation. Two of the three 
papers provided their ingredients and dosages; these were Sinn and Bryan (2007) and Nelson, et 
al. (1990). The third paper that did not find a significant effect was Perlman, et al. (2010). Perlman, 
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et al. (2010) did not provide the ingredients or dosages of the supplement administered to 
participants in the research paper or upon request; however, the supplement was described by 
the author as equivalent to over the counter multivitamins. 
Table 3 
Studies that Did Not Find a Significant Symptom Reduction. 
Micronutrient Supplement Psychological Area Explored Researcher’s Postulated 
Reason for Non-significant 
Result 
Sinn & Bryan (2007) Attention Deficit 
Hyperactivity Disorder 
(ADHD) symptoms 
Dosages too low for a clinical 
sample. 
Nelson et al. (1997) Intelligence Quotient (IQ) Trial period to short. 
Perlman et al. (2010) Academic Achievement Micronutrient composition 
possibly in-effective. 
 
The ingredients and dosages of the research and commercial micronutrients were 
recorded in one table under the headings: vitamins, minerals, amino acids, polyunsaturated fatty 
acids, and other ingredients, an excerpt from the full table can be seen in Appendix C. For each 
micronutrient supplement, both the dose and largest recommended daily dose was recorded. The 
amount of each nutrient at the largest daily recommended dosage for a child was then calculated. 
When recommended dosages were based on age, the dosage was calculated for the age bracket 
between eight and thirteen years of age. When the recommended dosage was weight based, the 
weight bracket less than or equal to 100 pounds was calculated. Once completed, the table 
contained 13 different effective research micronutrients supplements (see Table 4), and 22 
commercial micronutrients supplements (see Table 5). The number of times each vitamin or 
mineral occurred across the 13 research supplements was then calculated. The same process was 
then repeated for the 22 commercial products. This calculation allowed the comparison of the 
frequency with which a vitamin or mineral appeared in research supplements compared to 
commercial supplements. The dosage of each ingredient was then normalised to either 
micrograms (µg) or milligrams (mg). This normalisation was done to allow for ease of comparison 
across the supplements. For example, using the 30% International Unit conversion rate for vitamin 
A (retinol), 1 International Unit (IU) of vitamin A was re-recorded at 0.3 µg.   
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Table 4 
Effective Research Micronutrients and the Psychological Areas Explored 
Micronutrient Supplement* Psychological Area Explored 
1. Kumar M, & Rajagopalan S. 2008 Intelligence Quotient (IQ) 
2. Sandstead, H. et al., 1998 Intelligence Quotient (IQ) 
3. Osendarp, S. et al., 2007 Intelligence Quotient (IQ) 
4. Harrell R. et al., 1981 Down Syndrome Symptoms 
5. Xia, R. 2011 Autistic Spectrum Disorders (ASD) 
6. Schoenthaler et al., 2000 Intelligence Quotient (IQ) 
7. Harding et al., 2003 Attention Deficit Hyperactivity Disorder 
(ADHD) 
8. Adams et al., 2011 Autistic Spectrum Disorders (ASD) 
9. Klaire Laboratory Supplements Mood and General Behaviour 
Intelligence Quotient (IQ) 
10. Larkhall Laboratories Intelligence Quotient (IQ) 
11. Spectrum Support Vitamins & Minerals III Autistic Spectrum Disorders (ASD) 
12. EMPower Plus (including and after 2009) Paediatric Bipolar Disorder 
13. EMPower Plus (pre 2009) Mood and General Behaviour 
Notes: *Researchers are named as the micronutrient supplement when the supplement did 
not have its own name or was not given a name (i.e. was specifically created for the 
experiment). 
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Table 5 
Commercial Micronutrients 
1. Healtheries Fizz Bomb 
2. Healtheries Kidscare Chewables 
3. Healtheries Tongue Fizzer 
4. Blackmores Kid's Multivitamin 
5. Centrum Kids Complete 
6. Nature’s Own Child Care Multivitamin & Mineral 
7. Nature’s Sunshine Heroes Multiple Vitamin & Mineral 
8. Thompsons Animals Jnr Immunofort 
9. Radiance Kids Multivitamin 
10. Solgar Kangavites Complete Multivitamins & Minerals 
11. Emergen-C Kids Multi-Vitamin Fizzy Drink Mix 
12. Iceberg Labs KIDZ Multivitamins 
13. Rainbow Light Essential Gummies Multivitamin & Multimineral 
14. Essentials Children's Multi with Acidophilus 
15. Healtheries Teen Multi 
16. Flinstones Gummies Complete (Bayer) 
17. Children's Probiotic & Multivitamins (Lloyds pharmacy) 
18. Kindervital Tonic (Floradix) 
19. Every Day Please (Microgenics) 
20. Yummi Bears Multi-Vitamin & Mineral (Hero Nutritionals) 
21. Kordel's DHA Smart Multi 
22. Nature's Plus Animal Parade Chewable 
 
1.2. Active Compound Identification 
The micronutrient ingredients in the supplements were listed in a number of different 
forms for each vitamin or mineral. For example, vitamin C was listed in four different forms: 
ascorbic acid, sodium ascorbate, calcium ascorbate and mixed mineral ascorbates. To enable 
equitable comparison across the micronutrient supplements, the dose amount of the active 
compound in each of the different forms was calculated. The calculations for finding the active 
component of vitamin C in each of its given forms can be seen in Table 6. 
The active compound dose was not calculated for all of the nutrients. Vitamins were 
selected for the conversion based on their previously documented role in psychological 
functioning. The active compound dosage was calculated for vitamins: A, B1, B2, B3, B5, B6, B7 
(biotin), B9 (folic acid), B12, C, and D. The active compound dosage was not calculated for the 
minerals due to the complexity of identifying the correct chemical formula used in each mineral 
variation. This is highlighted in Table 7, where as an example, the percentage of zinc was 
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calculated for the six different forms of zinc used across the micronutrient supplements. Table 7 
indicates the difficulty in assuming the correct chemical formula, and therefore the zinc 
component of these mineral compounds. Different commercial suppliers of these minerals have 
varying chemical formulas, therefore only the average zinc component loading for these minerals 
could be presented. 
Table 6 
Calculations for finding Vitamin C (Ascorbic Acid) Component 
Vitamin C Form Rate of Conversion Calculation Vitamin C 
Component 
Sodium Ascorbate Ascorbic acid= 88.9% of sodium 
ascorbate 
120mg x 88.9% 
 
106.68 mg 
 
Calcium Ascorbate Ascorbic acid = 89.85% of 
calcium ascorbate 
900mg x 89.8%  808.2 mg 
Mixed Mineral 
Ascorbate 
Ascorbic acid = approximately 
88% of mixed mineral 
ascorbates 
500mg x 88% 440 mg 
 
Table 7 
Zinc Active Component Calculations 
Zinc Compound Chemical Formula Approximate Percentage  
of Zinc Present 
1. Zinc Oxide ZnO 80 % 
2. Zinc Amino Acid 
Chelate 
 
* 10 % 
3. Zinc Citrate 
 
34 % 
34 Zinc chelate * Based on EDTA 
(Ethylenediaminetetraacetic acid)  
* 12 % 
35 Zinc 
Monomethionate 
 
 
 
Not known 
36 Zinc Sulfate ZnSO4 40 % 
Notes: * As indicated by common commercial product loadings of zinc component. 
54 
 
1.3. Data Treatment  
Data analysis was carried out with the aim of identifying the vitamin dose properties across 
the studies that found a significant effect. Eighteen studies that provided their supplement 
ingredients fit this criterion, seen in Table 4. Each of the research supplement vitamins were 
converted to their active compound, and following this the median, maximum and minimum daily 
dose was calculated. In order to provide the most accurate picture of the data, the median was 
chosen as the measure of central tendency. This choice was made due to top end outliers. These 
outliers are reflected in the maximum values of the affected vitamins. The median vitamin dose in 
research supplements is the median dose found to have a psychological effect in a micronutrient 
supplement. This dose was calculated by ordering the doses from each study that found a 
significant effect and identifying the median dose value. The median, maximum and minimum 
dose calculations were then carried out on the commercial micronutrient vitamins. The final step, 
was the use of the non-parametric, two-tailed Mann-Whitney test, to identify whether the mean 
daily dosages of the research and commercial supplements were significantly different. 
2. Study 2: Why Do New Zealand Parents Give their Children Micronutrients? 
2.1. Participants 
Participants needed to be over 16 years of age, currently living in New Zealand and have at 
least one child under the age of eighteen residing in their household (did not have to be a 
biological child). Three hundred and sixty five parents participated in the survey. Of these 
participants, 95% were female and 5% were male. Eighty eight percent of participants were New 
Zealand European. The ethnicities of the remaining participants were as follows: 6% other 
European, 5% Maori, 1% Chinese. Participants in this sample were from a range of cities in New 
Zealand including: Auckland, Christchurch, Wellington, Dunedin, Hokitika, Taranaki, Taupo, 
Hastings, Oamaru, Waikato, Tauranga, Palmerston North and New Plymouth. The most common 
categories for employment status of participants was: trained service worker 20% (i.e. police, 
nurse), at home parent 32%, clerical or sales 9%, self-employed 7%, business manager or executive 
5%, professional worker 8% (i.e. lawyer, doctor) and manual worker 5%. 
2.2. Procedure 
 Participants were recruited via social networking advertisement. Advertisements were 
placed on multiple New Zealand based parenting websites (Kiwi Families, Parents Centre and the 
Parenting Place); the community thread on Trade Me, and were circulated via company emails 
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(The Press and Couplands). All advertisements displayed a website address that enabled 
participant’s access to the web-based survey. Once participants completed the survey they were 
offered the opportunity to enter a draw to win one of three $100 supermarket vouchers as a 
thank you for their time. Any information participants provided when entering the voucher draw, 
could not be linked to their survey responses, ensuring participants the anonymity of their 
responses.  
2.3. The Survey 
The web-based survey programme used to create the questionnaire was Qualtrics. Before 
completing the survey, respondents were directed to a web page with information regarding the 
question content of the study, the study’s purpose, and contact details of the primary researchers, 
as can be seen in Appendix A. This information page concluded by informing participants that any 
personal information given in the questionnaire could in no way be associated with their name, 
computer log-in or any other identifiable information. This information page also requested 
responders to give their informed consent to participate. Participants were informed that they 
could withdraw from the survey at any point without consequence.  
The number of survey questions was dependant on whether or not the respondent gave 
their child a micronutrient supplement. Respondents who indicated they purchase a micronutrient 
supplement for their child were asked to answer 19 questions, and those that did not purchase a 
micronutrient supplement were asked 12 questions, in both cases not all questions were 
mandatory. The survey took around five minutes to complete and is presented in Appendix B. The 
questions covered demographics, personal background, their child’s mental and physical health, 
and a number of factors based around their purchasing and administering of micronutrients (see 
Appendix B). The micronutrient based questions included: do any of the children in your 
household take any other type of supplement; for approximately how long have they taken a 
multivitamin; do they generally take the recommended dosage of multivitamin; for what reasons 
do you buy your child a multivitamin; what brand of multivitamin do you most often purchase; is 
there anything specific you look for in the ingredients; what factors are most influential in your 
choice of multivitamin; have you perceived any benefits from your child taking a multivitamin. All 
responses were obtained between April 16th and May 25th (2012). Respondents were again given 
the primary researchers details should they have any questions, or wish to further discuss any 
issues raised in the survey.  
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Results 
 
The results are presented separately for the micronutrient product and the survey 
investigation. Firstly, the frequency with which each vitamin or mineral appeared in research and 
commercial supplements is presented, followed by the descriptive statistics for each vitamin. The 
non-parametric comparison of the research and commercial dosages are presented. Following this 
is the descriptive statistics of each vitamin, including a graphical representation of the dosages 
across research and commercial supplements. Lastly, is an explanation for the removal of outliers 
from the dose sets. This reasoning is presented in both descriptive statistics and graphical form. 
 
1. Study 1: Micronutrient Product Investigation  
 The vitamin and mineral ingredients in the research and commercial supplements did not 
differ greatly. For example, thiamin appeared in 78% of the effective research supplements, and 
86% of the commercial supplements (seen in Table 8). Zinc also featured at a similar frequency in 
the research and commercial supplements: 77% of the research supplements and 82% of the 
commercial supplements (seen in Table 9). Out of all the vitamins and minerals, one ingredient was 
included in all of the supplements, this ingredient was pyridoxine. 
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Table 8 
The Frequency of Vitamin Inclusion in Each of the Micronutrient Supplements included in the Data 
Analysis 
Vitamin Percentage of Effective 
Research Supplements vitamin 
included in  
Percentage of Commercial 
Supplements vitamin included 
in 
Vitamin A 78% 95% 
Thiamin (B1) 78% 86% 
Riboflavin (B2) 78% 82% 
Niacin (B3) 85% 91% 
Pantothenic Acid (B5) 78% 95% 
Pyridoxine (B6) 100% 100% 
Biotin (B7) 46% 77% 
Folic Acid (B9) 78% 86% 
Cyanocobalamin (B12) 92% 100% 
Vitamin C 78% 100% 
Vitamin D 78% 91% 
Vitamin E 78% 95% 
Vitamin K 23% 14% 
Choline 54% 41% 
Inositol 54% 36% 
Notes: - Percentages are rounded to the nearest whole number. 
- In some cases supplements included multiple variations of the same vitamin. This is not 
represented in this data. 
- The research supplement percentages are based on the ingredients of effective micronutrient 
supplements that provided their ingredient and dose information. 
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Table 9 
The Frequency of Mineral Inclusion in Each of the Micronutrient Supplements included in the Data 
Analysis 
Mineral Percentage of Effective 
Research Supplements 
mineral included in 
Percentage of Commercial 
Supplements mineral included 
in 
Boron 23% 0% 
Calcium 69% 86% 
Chromium 69% 27% 
Copper 46% 27% 
Iron 69% 63% 
Iodine 54% 68% 
Fluoride 7% 0% 
Magnesium 69% 73% 
Manganese 77% 56% 
Molybdenum 69% 9% 
Nickel 15% 0% 
Phosphorus 23% 14% 
Potassium 46% 50% 
Selenium 62% 23% 
Silicon 7% 0% 
Sulphur 15% 0% 
Vanadium 23% 0% 
Zinc 77% 82% 
Notes: - Percentages are rounded to the nearest whole number. 
- In some cases supplements included multiple variations of the same vitamin. This is not 
represented in this data. 
- The research supplement percentages are based on the ingredients of effective 
micronutrient supplements that provided their ingredient and dose information. 
 
1.1. B Vitamins 
 The Table 10 displays the daily dose median and range for each B vitamin. The results 
indicate that research supplement B vitamin doses are higher than doses in commercial 
supplements. Table 10 also shows an overall broader dose range in the research supplements 
when compared to commercial supplements.  
  
59 
 
 
Table 10 
B Vitamin Median Daily Dose and Dose Distribution Properties in Research and  
Commercial Micronutrients 
Vitamin Research 
Supplement 
Median (SD) 
Commercial 
Supplement 
Median (SD) 
Research 
Supplement 
Minimum- 
Maximum Dose 
Commercial 
Supplement 
Minimum- 
Maximum Dose 
Thiamin (B1) 14.59 mg (11.52) 1.22 mg (0.89) 0.7 – 243.18 0.6 – 40.84 
Riboflavin (B2) 13.5 mg (12.84) 1.7 mg (2.11) 0.85 - 200 0.55 - 10 
Niacin (B3) 63.75 mg (36.87) 13.5 mg (5.43)  10 - 750                                   2.5 - 20
Pantothenic Acid (B5) 22.08 mg (54.76) 7.5 mg (2.56) 0.92 – 450.8 1.5 - 10 
Pyridoxine (B6) 23.04 mg (18.87) 1.78 mg (1.61) 0.9 – 287.95 0.7 – 8.23 
Biotin (B7) 400 µg (429.31) 50 µg (90.65) 10 - 150 10 - 1000 
Folic Acid (B9) 560 µg (703.48) 100 µg (132.52) 35 – 2048.5 5 - 400 
Cyanocobalamin (B12) 900 µg (490.71) 5 µg (2.04) 1 - 500 0.64 - 750 
  
 
As the data did not follow a normal distribution, a two-tailed Mann-Whitney test was 
conducted for each vitamin. The Mann-Whitney test was used to evaluate if the research and 
commercial supplements had significantly different daily doses. The results of all tests were in the 
expected direction, whereby the research supplement dose was larger than the commercial 
supplement dose. The effect size was calculated for each Mann-Whitney test, this was calculated 
using N (total number of supplements) and the Z score. The standard value of r for a small effect 
size is 0.1, 0.3 for a medium effect size and 0.5 for a large effect size. Outliers were removed before 
conducting non-parametric tests and dose distribution graphs. These extreme scores were 
removed to improve the test accuracy and reduce the errors of inference (Osborne and Overbay, 
2004). For each vitamin, no more than one outlier was removed from each of the supplement 
categories.   
The median thiamin daily dose for research and commercial supplements was 14.59mg and 
1.22mg respectively. The maximum research dose was 243.18mg and the maximum commercial 
dose was 40.84mg. Mann-Whitney test results indicated that the research and commercial 
supplements differed significantly from each other, U(29)= 36.5,  p < .01, r = .55 (see Table 11). This 
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difference is clearly highlighted in Figure 1 which shows the dose distribution across both research 
and commercial supplements, with research doses on the left side of the graph and commercial 
doses on the right.  
 
 
Figure 1. Thiamin Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
 
The median riboflavin daily dose was 13.5mg in the research supplements and 1.7mg in the 
commercial supplements. Test results show that the research riboflavin daily dose was significantly 
higher when compared to the commercial riboflavin dose, (U (32)= 62.5, p < .05, r = .43, see Figure 
2).  
 
Figure 2. Riboflavin Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
Thiamin Daily Dose (mg): 
Research versus Commercial Supplements 
Riboflavin Daily Dose (mg): 
Research versus Commercial Supplements 
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The niacin median daily dose in research and commercial supplements was 63.75mg and 13.5mg 
respectively. The research and commercial niacin doses were found to be significantly different U 
(32)= 41.5, p < .05, r = .56. This significant group difference is highlighted in Figure 3, as the 
research daily doses of niacin are clearly overall larger than the commercial doses.  
 
 
 
 
Figure 3. Niacin Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
 
Niacin Daily Dose (mg): 
Research versus Commercial Supplements 
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Table 11 
Nonparametric test of group difference in Daily Dose Between Research and Commercial Micronutrient 
Supplements. 
Vitamin U  
(Mann-Whitney) 
Z N 
(Total Number) 
Significance  
(2 tailed) 
r  
(Effect Size) 
Thiamin (B1) 36.5 -2.96 29 .003 .55 
Riboflavin (B2) 62.5* -2.42 32 0.16 .43 
Niacin (B3) 41.5 3.16 32 0.002 .56 
Pantothenic Acid 
(B5) 
21 -3.95 33 0.000 .69 
Pyridoxine (B6) 79 -2.88 38 0.004 .47 
Biotin (B7) 26 -3.08 27 0.002 .59 
Folic Acid (B9) 44.5 -3.25 33 0.001 .57 
Cyanocobalamin 
(B12) 
75 -2.68 36 0.007 .45 
Vitamin A 120 * -1.06 35 0.289 .18 
Vitamin C 56.5 -3.06 35 0.002 .52 
Vitamin D 74.5 -2.19 33 0.029 .38 
Note:  * U values are not significant. 
Small effect size 0.1, medium effect size 0.3, large effect size 0.5. 
 
The research median dose was also higher than the commercial supplement median for 
pantothenic acid (research Mdn 22.08mg, commercial Mdn 7.5 mg, see Table 11). The pantothenic 
acid dose in research supplements was significantly higher than the commercial supplements dose, 
U(33) = 21, p < .001, r = .69, which can be clearly seen in the dose distribution in Figure 4. 
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Figure 4. Pantothenic Acid Daily Dose Distribution (Research supplement doses on the left side 
coded on horizontal axis as 1.00; commercial supplement doses on the right side coded on the 
horizontal axis as 2.00). 
 
 
The research median daily dose for pyridoxine was 23.04mg, in contrast to the commercial median 
of 1.78mg. The difference between the research and commercial daily doses of pyridoxine was 
found to be significant, U (38)= 79, p <.01, r = .47. This significant dose difference is highlighted in 
Figure 5.  
 
 
Figure 5. Pantothenic Acid Daily Dose Distribution (Research supplement doses on the left side 
coded on horizontal axis as 1.00; commercial supplement doses on the right side coded on the 
horizontal axis as 2.00). 
 
The research and commercial biotin dose medians were 300μg and 50μg, respectively. The biotin 
daily dose was found to be significantly different in the research compared to the commercial 
Pantothenic Acid Daily Dose (mg): 
Research versus Commercial Supplements 
Pantothenic Acid Daily Dose (µg): 
Research versus Commercial Supplements 
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supplements as can be seen in Figure 6, (U(27) = 26, p <.01, r = .59). 
 
 
Figure 6. Biotin Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
 
The folic acid median daily dose in research supplements was 560μg and 100μg in commercial 
supplements. The doses in these two groups were found to be significantly different, U (33)= 44.5, 
p = .001, r = .57, a difference clearly represented in the dose distribution shown in Figure 7.  
 
 
 
Figure 7. Folic Acid Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
Biotin Daily Doses (µg): 
Research versus Commercial Supplements 
Folic Acid Daily Doses (µg): 
Research versus Commercial Supplements 
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The research and commercial daily doses of cyanocobalamin (B12) were found to be significantly 
different, U(36) = 75, p < .01, r = .45. The median B12 dose was 900μg for the research supplements 
and 5μg in the commercial supplements. This significant difference in daily doses between 
research and commercial supplements can be seen clearly in Figure 8.  
 
 
Figure 8. Cyanocobalamin Daily Dose Distribution (Research supplement doses on the left side 
coded on horizontal axis as 1.00; commercial supplement doses on the right side coded on the 
horizontal axis as 2.00). 
 
1.2. Vitamins A, C and D 
 Table 12 displays the daily dose median and range for vitamins A, C and D. The results 
again indicate that research supplement vitamin doses are higher than doses in commercial 
supplements. Similarly to the B vitamins, the dose range properties for vitamins A and C also 
indicate an overall broader dose range in the research supplements when compared to commercial 
supplements.  
The median dose of vitamin A in the research supplements was found to be 1500µg, and in 
the commercial supplements 900µg. This difference in the research and commercial supplement 
vitamin A doses was not significant, U(35) = 120, p = n.s, r = .18. The dose distribution of vitamin A 
in research versus commercial supplements is demonstrated in Figure 9 which indicates more 
overlap between research and commercial doses than the B vitamins. 
Cyanocobalamin Daily Doses (µg): 
Research versus Commercial Supplements 
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Table 12 
Vitamin A, C and D Median Daily Dose and Dose Distribution Properties in Research and Commercial 
Micronutrient Supplements 
Vitamin Research 
Supplement 
Median (SD) 
Commercial 
Supplement 
Median (SD) 
Research 
Minimum- 
Maximum Dose 
Commercial 
Minimum- 
Maximum Dose 
Vitamin A 1500µg (1416.36) 900µg (861.27) 300 – 4512.8 15 - 3000 
Vitamin C 600mg (386.8) 60mg (25.73) 26.6 - 1500 20 - 500 
Vitamin D 10µg (13.59) 7.5µg (3.5) 2.5 - 40 2.5 - 360 
 
 
 
 
Figure 9. Vitamin A Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
 
The research and commercial supplement daily doses of vitamin C were found to be significantly 
different, U(35) = 56.5, p < .01, r = .52. The median vitamin C dose was 600mg for the research 
supplements and 60mg for the commercial supplements. This significant difference in daily doses 
between research and commercial supplements can be seen clearly in Figure 10.  
Vitamin A Daily Dose (µg): Research versus Commercial 
Supplements 
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Figure 10. Vitamin C Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
 
The vitamin D doses in the research and commercial supplements were found to be significantly 
different, U (33)= 74.5, p < .05, r = .38. The median daily dose of vitamin D in research supplements 
was 10μg, and 7.5μg in commercial supplements. This difference is better illustrated in the dose 
distribution shown in Figure 11.  
 
Vitamin C Daily Doses (mg): 
Research versus Commercial Supplements 
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Figure 11. Vitamin D Daily Dose Distribution (Research supplement doses on the left side coded on 
horizontal axis as 1.00; commercial supplement doses on the right side coded on the horizontal 
axis as 2.00). 
 
 
1.3. Outliers 
Before using the Mann-Whitney test to assess whether the independent groups (research 
supplements and commercial supplements) were significantly different from one another, outliers 
were removed from the data. The initial identification of these extreme data points was done by 
means of graphical inspection, demonstrated in Figure 12 , where research doses are shown on the 
left, and commercial on the right. Each colour represents the dose distribution for vitamins thiamin 
(B1), riboflavin (B2), pantothenic acid (B5) and pyridoxine (B6). These four vitamins are represented 
because they are all in milligrams and fall within a similar numerical range. The data points that 
were removed as outliers, marked with an arrow, are clearly identifiable as extreme in each data 
set.   
The extreme data points that were removed before group comparison analysis are given in 
Tables 12 and13. A total of 11 vitamins were analysed. From the research supplements six outliers 
were removed, and from the commercial supplements five outliers were removed. In Table 13 the 
large difference between these extreme data points and the median dose is clear. For example, the 
median thiamin (B1) dose in research supplements was 14.59mg, and the extreme dose declared 
an outlier was 243.18mg. The next closest thiamine dose in the research supplements was 
40.14mg. The biotin (B7) commercial supplement median dose was 50μg, and the extreme dose 
Vitamin D Daily Doses (µg): 
Research versus Commercial Supplements 
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identified as an outlier was 1000μg. The next closest biotin dose was 300μg. The cyanocobalamin 
(B12) commercial supplements daily dose median was 5μg, and the extreme data point removed 
before analysis was 750μg. The closest cyanocobalamin dose in the commercial supplements to 
this extreme value was 10μg. 
 
Table 13 
Research Supplement Outliers Removed from Data Analysis 
Vitamin Median Outlier removed 
Thiamin (B1) 14.59 mg 243.18 mg 
Riboflavin (B2) 13.5 mg 200 mg 
Niacin (B3) 63.75 mg 750 mg 
Pantothenic Acid (B5) 22.08 mg 450.8 mg 
Pyridoxine (B6) 23.04 mg 287.95 mg 
Vitamin C 600 mg 1500 mg 
 
 
Table 14 
Commercial Supplement Outliers Removed before Data Analysis 
Vitamin Median Outlier removed 
Thiamin (B1) 1.22 mg 40.84 mg 
Biotin (B7) 50 μg 1000 μg 
Cyanocobalamin (B12) 5 μg 750 μg 
Vitamin C 60 mg 500 mg 
Vitamin D 7.5 μg 360 μg 
 
In many cases the Mann-Whitney test results still indicated a significant group dose 
difference, before the outliers were removed. For example, the research and commercial 
supplement dose for thiamin (B1) was found to be significantly different, U(29) = 36.5,  p < .01, r 
= .55. If this data analysis is conducted with the inclusion of the outliers, that is 243.18mg in the 
research supplement category and 40.84mg in the commercial supplements, the difference would 
still be significant, U(31) = 49.5, p < .01, r = .50. 
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Figure 12: The distribution of doses in vitamins B1, B2, B5 and B6. The research supplement doses are on the left hand side of the graph, and the commercial doses 
are on the right hand side of the graph. The arrows indicate the outliers that were removed before the data analysis was conducted. 
Vitamins B1, B2, B5 and B6 Distribution of Doses, with Marked Outliers 
Thiamin (B1) 
Riboflavin (B2) 
Pantothenic Acid (B5) 
Pyridoxine (B6) 
71 
 
 
2. Study 2: Survey 
 
In the following section, an overview of participant characteristics is provided. Then 
the purchasing habit characteristics of the parents who purchase micronutrients for their 
child are described, and the rationale surrounding their choice to purchase these nutrients is 
presented. Thirdly, the parents perceived benefits of micronutrient administration are 
described. 
 
2.1. Overview of Sample Characteristics 
This survey was predominantly answered by females, as female respondents 
represented 95% of the total participants. A large majority of respondents were married 
(70%), with the next most common relationship status being in a de-facto relationship 
(19%). Participants most commonly identified with being New Zealand European (88%), with 
other European and Maori being the next biggest ethnicity groups. In this sample the 
distribution of highest qualifications earned was broad, with 29% having earned a bachelor’s 
degree, 23% completed the final year of high school, 14% earned a post graduate diploma, 
and 13% completed less than final year of high school. 55% of participants had an average 
gross household income between $35,000 and $99,000, and 31% of participants had an 
average household income of $100,000 or greater.  
Respondents had an average number of 2 children in their care at the time of the 
study (47%), with one child and three child households equally occurring (21% each). The 
children’s age distribution was as follows: 0-2 years 34%, 3-4 years 36%, 5-6 38%, 7-8 years 
29%, 9-10 years 21%, 11-12 years 16%, 13-15 years 20% and 16-18 years 12%. From these 
children the most commonly reported physical ailments were: 88 who were reported as 
suffering from asthma, 26 from bedwetting, 71 as suffering from allergies, and eight with 
eczema. The most common mental health related disorders reported were: 13 with 
Asperger’s, 12 with autism, 11 with dyslexia, 10 children were identified as having an anxiety 
disorder, nine with ADHD, and eight with auditory processing disorder. 
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2.2. Who Purchases Micronutrient Supplements?  
Out of 365 parents, 232 give their child a multivitamin supplement (64%). A large 
portion of these parents also gave their child another supplement in addition to a 
multivitamin. The most common additional supplements parents purchased for their child 
were vitamin C (100 parents), and fish oil/omega 3 (69 parents). Fifty (22%) of the 232 
parents indicated that they did not give their child any supplements in addition to a 
multivitamin.  
Parents reported that their child had taken a multivitamin supplement for a range of 
time periods: for years 35%, a year 16%, months 27% and weeks 14%. Respondents 
indicated that 76% of their children take the recommended dosage of their multivitamin 
supplement. Also indicated was that 18% of children generally were given less than the 
recommended dosage. The most common child micronutrient brands purchased were 
Thompsons 40%, Healtheries 28%, Centrum 15% and Blackmores 12%.  
In this sample of New Zealand parents, the ethnicity of the participants who 
indicated they purchase a micronutrient supplement for their child were NZ European 87%, 
Other European 6%, Maori 4%, Samoan 0.4%, Indian 0.4%, Canadian 0.8%, Australian 0.8% 
and Other 0.8%. The ethnicity of the participants who did not give their child a multi 
micronutrient supplement was 82% NZ European, Other European 8%, Maori 6%, Samoan 
0.7%, Chinese 1%, Aborigine 0.7%, and Other 1%. An ethnicity comparison between these 
two groups shows only a minor increase in the representation of Maori and Pacific Islanders 
in the participants who do not give their child a micronutrient supplement. 
Participants were asked to indicate an estimate of the gross household income this 
question however, was not compulsory. Consequently this question was only answered by 
261 participants. Of the 221 participants who give their child a micronutrient supplement 
and responded to this question, the household income was as follows; 4% earned $16,000 
through to $24,999, 5% earned $25,000 through to $34,999, 10% earned $35,000 through to 
$49,999, 26% earned $50,000 through to $74,999, 17% earned $75,000 through to $99,999, 
31% earned $100,000 or greater, and 7% did not know their household income. These 
results indicate that 74% of participants who gave their child a micronutrient supplement 
had a gross household income between $50,000 through to $100,000 and above. The gross 
household income for the 40 participants who do not give their child a micronutrient 
supplement, was reported as follows; 10% earned $35,000 through to $49,999, 27.5% 
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earned $50,000 through to $74,999, 27.5% earned $75,000 through to $99,999, and 35% 
earned $100,000 or greater.  Due to the small number of question completers from the 
participant group that does not give their child a micronutrient, the household incomes 
reported cannot be relied upon to accurately represent this group.  
 
2.3. Why Parents Administer Micronutrients 
The analysis revealed that there are a number of motivators behind the purchasing of 
child micronutrient supplements. These can be seen in Table 14 which lists the motivators in 
order of popularity. The most common reasoning was to prevent colds or illnesses, 129 
respondents (23%). The other top motivators were: confidence that their child is getting a 
balanced diet (15%),  their child is a picky eater (13%), to improve their child’s mental acuity 
(8%) and because their child is run down (7%). Of the 7% of parents who purchase 
multivitamins for other reasons, none specified motivators that were psychologically based. 
Over two thirds (71%) of these parents do not look for anything specific in the multivitamin 
ingredients when purchasing a supplement. Of those 29% of parents who look for a specific 
ingredient, the most commonly targeted ingredients were vitamin C, iron and a variety of or 
high dosage of B vitamins. The most influential factor for parents when choosing a 
multivitamin for their child firstly was the price, and secondly was their child’s preference in 
taste. These factors were closely followed in popularity by the ease of consumption for their 
child, whether the supplement is chewable and the supplement brand. 
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Table 15 
Reasons Parents Purchased Multivitamins for their Children  
Motivations Response Number Response % 
Prevention of colds or illnesses 129 24 
It gives me confidence that they are 
getting a balanced diet 
86 16 
My child is a picky eater  75 14 
To improve my child's mental acuity (i.e. 
their intelligence, cognition) 
44 8 
Because my child is run down  41 8 
Other 39 7 
To improve my child's ability to focus 31 6 
The doctor recommended multivitamins  26 5 
Because I read that multivitamins were 
good for children 
15 3 
Because my child has a mental health 
disorder e.g. ADHD, autism, dyslexia, 
depression 
15 3 
Because I was given a multivitamin as a 
child 
9 2 
Because my child suffers from a disease 8 2 
To help reduce my child's anxiety 6 1 
Because a fellow parent recommended 
them 
5 1 
Don’t know 1 0 
Note:  
- Highlighted areas are psychologically based motivations.  
- Participants were asked to choose all reasons that applied to their situation.  
- Participant’s motivations for purchasing multivitamins for their children are 
listed in order of popularity.  
- Response percentages are rounded to the nearest whole number. 
 
Parents were able to select or specify multiple reasons for their purchasing of a 
multivitamin for their child. Respondents reported a range of benefits that they have 
perceived as a consequence of giving their child a multivitamin supplement. The most 
commonly reported benefit was that their child gets ill less often or with less severity (113 
respondents, 49%). Another benefit commonly perceived was that their child recovered 
from illness faster (27%). Other benefits parents perceived in their child were: more energy 
(17%), improved focus (9%), and improved behaviour (9%). Thirty percent of parents who 
give their child a multivitamin reported seeing no direct benefits.  
2.4. Perceived Benefits of Micronutrient Administration  
Of those respondents who indicated one of their motivators for purchasing a 
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multivitamin was to improve their child’s mental acuity, 6.8% reported that as a result of 
their child taking a multivitamin  they noticed an improvement in their child’s mental acuity. 
Twenty seven percent of the parents who indicated their reasoning for purchasing 
multivitamins included to improve their child’s mental health disorder, perceived an 
improvement following their child’s use of multivitamins. From those parents who reported 
that a reason for purchasing a multivitamin was to improve their child’s ability to focus, 42% 
perceived a benefit in their child’s focus. Of the six parents who indicated that they purchase 
a multivitamin to help reduce their child’s anxiety, three (50%) reported that they perceived 
an improvement in their child’s anxiety following multivitamin administration. Overall, of 
those parents whose motivations for purchasing multivitamins were psychologically based, 
24% perceived an improvement in the targeted psychological area. In addition, from this 
group of parents, 15 perceived an improvement in their child’s general behaviour. 
Healtheries was clearly the most popular choice of supplement brand for the parents whose 
motivations to purchase a micronutrient supplement for their child included a 
psychologically focussed purpose, with 20% of parents most commonly choosing this brand. 
The second most popular supplement brand among this group was Blackmores, at 10%. 
 
Discussion 
These studies addressed the composition and use of micronutrients given to 
children. To address this, three aims were investigated across two studies; Study 1, a study 
of micronutrient composition and Study 2, an examination into the motivation to use 
micronutrients. The first study consisted of two aims. The first aim was to compare the 
ingredients of micronutrient supplements that were effective in research to the ingredients 
in commercial micronutrients. The second aim was to compare the doses in research 
micronutrients to the doses in commercial micronutrient supplements. There was one aim 
in Study 2; identify why New Zealand parents give their child a micronutrient supplement. 
The discussion will be sectioned according to each research focus. Firstly, describing 
and discussing the composition of micronutrient supplements in both research and 
commercial settings. Followed by a discussion of the reasons parents give their child a 
micronutrient supplement, and the associated characteristics such as perceived 
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micronutrient benefits and the factors that are influential on the choice of micronutrient 
supplement brand. 
1. Micronutrient Supplement Composition 
The composition of ingredients in the research and commercial supplements did not 
differ greatly. The vitamins appeared in general as frequently in the research products, as 
they did in commercial supplements. There were some differences in supplement 
ingredients among the minerals, whereby research supplements were found to include a 
marginally wider variety of minerals than the commercial supplements. An example of this 
was molybdenum, which was found in 69% of research supplements, but just 9% of 
commercial supplements. Prevalence differences similar to those found with molybdenum 
were also found between the research and commercial supplements for selenium and 
chromium.  Vanadium and boron were not included in the ingredients of commercial 
supplements; however, they were included in the ingredients of 23% of the micronutrient 
supplements used in research.  The findings indicated that the research and commercial 
supplements were not greatly different in their choice of vitamin or mineral ingredients with 
the exception of some minerals.  
The minerals found notably more in the research supplements were selenium, 
vanadium, boron and molybdenum. Selenium plays an important role in thyroid 
metabolism, therefore it may play a role in psychological facets, for example irritability and 
tiredness (Arthur, 1991). Vanadium, boron and molybdenum however, are not commonly 
discussed as playing major roles in mental and psychological health (Young, 2002). The 
before mentioned mineral roles in psychological health indicate that the differences in 
effectiveness that may be suggested between research and commercial supplements, are 
not likely to be contributable to the choice of minerals or vitamins in supplements, as the 
vitamins and minerals have in general, a similar occurrence across the research and 
commercial supplements. It should be noted that this comparison did not take into account 
the different forms of each vitamin or mineral used in the supplements. If the comparison 
had been adjusted to also reflect the different forms of the nutrients, the ingredient 
frequency findings may have been different between the research and commercial 
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supplements, however due to the time constraints of a Master’s thesis has not been further 
investigated.  
The vitamin included in all the supplements analysed was pyridoxine (B6), indicating 
that pyridoxine may play an important role in the combination of nutrients used in 
micronutrient supplements. Pyridoxine is involved in the synthesis of a number of 
neurotransmitters including serotonin, dopamine, acetylcholine, norepinephrine and GABA 
(Dakshinamurti et al. 1990). These neurotransmitters are heavily associated with 
depression, mood, sleep, attention, appetite, and anxiety (Tasman et al. 1997). Although, 
pyridoxine was included in all of the analysed supplements, the median dose of pyridoxine 
was significantly different between the research and commercial supplements. The median 
commercial daily dose approximated the RDI dose of 1mg for New Zealand children aged 
between 9 and 13 (NHMRC, 2006), the median daily dose in research supplements was 
much higher, at approximately 23mg. The higher research supplement dose may indicate 
that B6 levels significantly above the RDI are necessary to effectively impact on mental and 
emotional psychological symptoms. 
Following vitamin B6 in popularity in supplement ingredients was vitamin B12. B12 was 
included in the ingredients of all commercial supplements sampled, and almost all of the 
research supplements indicating that B12 may also play an important role in the combination 
of ingredients used in micronutrient supplements. The psychological effects of B12 deficiency 
include adverse effects on cognition from adolescence years onwards (Louwman et al 2000), 
indicating that B12 may have a role in the improved cognition found in the multiple cognition 
studies discussed. The RDI for New Zealand children aged between 9 and 13 is 1.8µg 
(NHMRC, 2006), which is lower than the 5µg commercial supplement daily dose median and 
significantly lower than the research median dose of 900µg. The notable difference 
indicates that achieving a significant change in mental and emotional symptoms may 
require B12 doses significantly greater than the RDI for New Zealand children. 
The median daily doses were found to be greater in the research supplements than the 
commercial supplements across all of the vitamins analysed, these included the vitamins: A, 
B1, B2, B3, B5, B6, B7 (biotin), B9 (folic acid), B12, C, and D. These differences were revealed to 
be significant by a non-parametric, two-tailed Mann-Whitney test for all of the vitamins with 
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the exception of vitamin A and riboflavin (B2).  The median vitamin A daily dose was found 
to be 1.7 times greater than the commercial daily dose. This difference was not significant, 
with a p value of approximately 0.3. Although more overlap is shown in the graphical 
representation of the daily doses with a significant group difference(see Figures 
1,3,4,5,6,7,8,9,10, 11), a greater overall dosage is still noticeable in the vitamin A research 
doses (see Figure 9), a finding which is also true for B2 (see Figure 8). These results indicate 
that research and commercial micronutrient supplements have significantly different 
vitamin dosage compositions. The most important ramification of this significant difference 
may be the inability to generalise micronutrient research findings to over-the-counter 
commercially available micronutrient supplements.  
For New Zealand parents, this means that the micronutrient supplements available 
in supermarkets, health food stores and pharmacies, are unlikely to be as effective as the 
supplements used in research when targeting behavioural change. A number of 
micronutrient products available in New Zealand indicate that their ingredients have 
psychological benefits. Although the characteristic information of the nutrient that they 
present is correct, the information may also be misleading. Based on research supplement 
composition, it appears that the psychological benefits found as a result of micronutrient 
administration are obtained through doses much higher than the doses in the micronutrient 
supplements that they have provided the information in conjunction with. For example, the 
company Kordel, includes this quote in their on-line product information for Kordel’s Smart 
Multi: “Nutritional research indicates that infants and children with increased DHA intakes 
have higher IQ scores, improved cognitive function, learning abilities and behavioural skills.” 
The DHA dose in this Kordel multivitamin supplement is 26mg. In the 2008 study 
investigating whether DHA supplementation was linked to improved cognitive skills, the 
effective daily dose amount of DHA given to preschool participants was 400mg (Nelson, 
2008). Although the product does not claim to provide these results, the inclusion of this 
information with the product’s description may lead consumers to think that this product 
would produce a similar effect, which is unlikely when the product dose is significantly lower 
when compared to the effective research dose. 
The most significant differences in doses between research and commercial 
supplements were found to be in pantothenic acid (B5) and folic acid (B9). The significantly 
79 
 
larger research supplement doses of pantothenic acid and folic acid are unsurprising given 
their roles in mental health.  
Pantothenic acid has a number of important roles in mental and psychological 
health. As a component of CoA, pantothenic acid plays an important role in the synthesis of 
vitamins A and D and neurotransmitters, and when combined with choline produces 
acetylcholine, a neurotransmitter with important roles in memory, attention and cognitive 
functions (NHMRC, 2006). The median dose amount in research supplements was found to 
be approximately four times higher than the AI of 5mg for boys and 4mg for girls. The dose 
in commercial supplements was much closer to the AI, with a median daily dose of 
7.5mg.The high dose found in research supplements is unlikely to cause adverse health 
effects as there have been no indications of adverse health effects in either humans or 
animals (Wellington: Ministry of Health, 2011).  
Folic acid also plays a key role in psychological processes. It is used in the 
manufacturing of neurotransmitters, and is a cofactor in the synthesis of serotonin. Folic 
acid is vital in helping to maintain normal serotonin levels; consequently, depression is a 
common symptom of folic acid deficiency (Alpert, 1997). The median research daily dosage 
of 560 µg is 260µg above the RDI (NHMRC, 2006) for children aged between 9 and 13. 
Although much higher than the 100µg commercial supplement median, the research daily 
dosage is still well below the LOAEL, which was set at 5mg daily (NHMRC, 2006). 
The Journal of the American Medical Association (JAMA) (Fletcher & Fairfield, 2002) 
showed that the North American Diet, while sufficient to prevent vitamin deficiency 
diseases, is inadequate to support optimal health. Fletcher and Fairfield also noted a 
growing concern among nutrition experts that the RDA’s for vitamins and minerals are too 
low. The United States RDA guideline levels in 2002 were similar overall to those set by the 
NHMRC (2006) guidelines, with the RDA of some vitamins in the New Zealand guidelines set 
marginally higher, and others marginally lower. The American RDA levels are established to 
prevent acute vitamin deficiency disorders however evidence suggests that higher levels of 
many vitamins and mineral are necessary to achieve optimum health (MacWilliam, 2009). 
The assessment made by the JAMA that RDA values are set too low, is supported by the 
almost unanimously higher median vitamin daily dose’s (with the exception of niacin and 
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folic acid in the commercial supplements) found in both the research and commercial 
supplements. This difference was most evident in the median research cyanocobalamin 
dose which was found to be 500 times greater than the RDA set by the NHMRC (2006) 
guidelines. This high vitamin intake is unlikely to produce adverse effects, possibly because 
of the body’s ability to decrease absorption in response to high intakes (UK Expert Group on 
Vitamins and Minerals, 2002). The commercial median daily dose was also greater than the 
RDA, at 2.8 times greater than the recommended daily dose. 
It is possible that the dosages in commercial supplements are significantly lower 
than the dosages in research supplements due to the increased cost of larger nutrient 
doses, and the cost of superior raw materials used in the preparation of the research 
micronutrient products. There were 13 effective research supplements and the prices were 
available for two of these. Using these supplements as a cost guide for the research 
supplements, the average cost of a research supplement when used in a treatment setting 
was $6.90 daily. The average price of the 22 commercial products was 64cents for a daily 
dose. This large difference in the daily cost of providing a child with a micronutrient 
supplement is likely to be a significant reason for the low doses found in commercial 
products, as it is unlikely parents are willing to pay for higher doses. This is supported by the 
survey finding that price may be the most influential factor when New Zealand parents are 
choosing a multivitamin for their child. 
2. Motivations Behind Micronutrient Use 
Eighteen percent of parents identified a psychologically based reason as one of their 
key motivations for purchasing a micronutrient supplement for their child. This low 
percentage of parents confirms the hypothesis that the majority of parents in New Zealand 
do not purchase a micronutrient supplement to improve their child’s psychological well-
being. Parental motivations for purchasing micronutrient supplements were found to be 
largely based on physical health. The most common motivating factors for a New Zealand 
parent to purchase a micronutrient supplement were the prevention of colds or illnesses 
and the confidence it gave them that their child was getting a balanced diet.  
The survey results suggest that efficacy at the commercial supplement doses is not 
present, as overall just 24% of parents whose motivations for purchasing multivitamins were 
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psychologically based, perceived an improvement in the psychological area they were 
targeting. This indicates that the parents who give their child a supplement for a 
psychologically based reason do not perceive a behavioural modification after 
supplementation. It is possible that this finding is not completely accurate as parental 
perceptions without a methodologically sound measuring tool may not accurately perceive 
changes in their child’s behaviour. Changes resulting from micronutrient supplementation in 
physical symptoms such as how often a child gets a cold or flu, are easier for parents to 
perceive as they can compare of how often the child has a cold or flu compared to the 
child’s friends. It is possible that this ease of reference of change is reflected in the 49% of 
parents who identified that their child gets ill less often or with less severity following 
micronutrient supplementation. 
The survey identified that a number of parents (18%) generally give their child less 
than the recommended dose of a micronutrient supplement. The lower dosages some 
children receive may provide an additional reason as to why parents in general do not 
perceive psychological benefits from their child’s micronutrient use. For parents this may be 
a price sensitive choice, as parents indicated the most influential factor when selecting a 
multivitamin was the price. 
3. Strengths and Limitations 
3.1. Strengths of Study 1.  
A strength of this analysis was the wide range of New Zealand over the counter 
supplements that were sampled. The sample of products contained 12 different brands of 
micronutrient supplements sold over the counter in New Zealand. This broad sample of 
supplements might mean that the commercial supplement characteristics calculated in this 
study are highly representative of the micronutrient products aimed at children that are 
available over the counter in New Zealand. 
3.2. Limitations of Study 1.  
There are a number of limitations involved in this micronutrient supplement 
analysis. The first of these is that the frequency of nutrient inclusion comparison, did not 
account for the different forms of each nutrient. The vitamins and minerals were found in a 
number of different forms across the supplements. In-depth analysis of the forms of each 
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mineral and vitamin may provide further important information to guide a decision as to 
whether or not these ingredients are comparable. This in-depth analysis is important 
because the form of a nutrient indicates the amount of specific mineral or vitamin 
contained. For example, retinyl palmitate which is a form of vitamin A, contains 54.7% of 
vitamin A compared to; retinol acetate, which contains 87% of vitamin A (NHMRC, 2006).  
 A further limitation of this study was using the pure vitamin component for the dose 
calculations. This is not representative of the amount of vitamin that would be readily 
absorbed after entering the body, as different forms of a nutrient can have differing levels 
of absorption. The bioavailability is affected by the polarity (water solubility) of the 
compound. For example, the palmitoyl ester of vitamin A shown in Figure 13, is very much 
less polar than vitamin A itself, which will significantly affect it’s absorption from the 
gastrointestinal tract and thus it’s bioavailability. When there are significant differences in 
the bioavailability of forms of a nutrient, it would make a noticeable difference to the pure 
vitamin dose amount if it was to be altered to reflect the nutrient absorption properties. To 
remedy this problem, further data analysis would be required. Each type of vitamin would 
need to be adjusted according to its bioavailability, before conversion to the active vitamin 
compound dose.  
 
Figure 13: The molecular structure of vitamin A and vitamin A palmitoyl 
ester. A demonstration of the difference in their bioavailability. 
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The largest limitation of this study is a result of to the large number of ingredients 
contained in the supplements. There were 73 other ingredients and 17 minerals recorded 
across the range of supplements. Within some of the minerals or other ingredients are 
ingredients that contain vitamin components that have not been included in the total 
vitamin doses. The reason the vitamin components were not extracted from these 
ingredients was the complexity involved in identifying the correct chemical formula used in 
each ingredient variation within the other ingredients and minerals, and the inability to 
complete this task within the time constraints of a Master’s thesis. To obtain the most 
accurate median vitamin dose in both the research and commercial supplements, the active 
compounds need to be calculated for every ingredient in every supplement. 
 The lack of randomised double blind, placebo controlled trails in the scientific 
literature, especially in the treatment of psychological disorders, also places a limitation on 
this study. All study types were included when identifying effective research supplements 
for analysis in this study. The most common types of studies included in the analysis were 
open label. An open label study describes the situation when both the researcher and the 
participant in a research study are aware of the type of treatment the participant is 
receiving. The largest problem with these trials is the possible expectancy effect that can 
occur as a result of the symptom evaluator knowing that the child is receiving a supplement. 
In some of the studies included in the analysis the parents were the sole evaluator of 
behaviour during the trial period (Kaplan et al. 2002).  
The commercial supplements sampled were randomly selected from those available 
over the counter in New Zealand, and a small sample of popular micronutrient supplements 
available over the counter in the US, UK and Australia. The analysis did not include all 
micronutrient supplements available in New Zealand. An attempt was made to include a 
child directed micronutrient supplement from all brands sold over the counter in New 
Zealand, to attempt to ensure that the sample used in this analysis was be an accurate 
representation of what is available over the counter in New Zealand. 
Notwithstanding these limitations, the results of this study clearly suggest that 
differences in composition between effective research micronutrient supplements and 
commercial supplements do exist.  
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3.3. Strengths of Study 2.   
A strength of this survey was the large sample size. The minimum number of survey 
respondents this survey aimed to recruit was 100 participants who purchase micronutrients. 
This survey had 365 participants, 232 of which purchased a micronutrient supplement for 
their child, surpassing the minimum number of participants sought. 
A web based survey was the most practical approach to this data collection, as the 
literature suggests it is the most efficient method for the least biased participant responses 
and the best option for optimising subject recruitment, especially in terms of sample size 
(Krantz & Dalal, 2000). Research suggests that there is little difference in the data collected 
by web based surveys when compared to traditional methods (Krantz & Dalal, 2000). An 
advantage of using a web based survey was that participants could access and complete the 
survey in their own time, 24 hours a day. An additional benefit was that the recruitment 
process is simple, with advertising in the form of an on-line link which makes the survey 
readily accessible, and as reflected in the participant numbers, these advantages naturally 
produce higher survey participation. 
3.4. Limitations of Study 2 
This survey was predominantly answered by females (95%), meaning 5% of respondents 
were male. Although this represents a skewed sample of the population, it may not affect 
the results of the survey as the key points of interest were parents purchasing habits of 
micronutrients for their children, with a focus on parent’s key motivations for purchasing 
micronutrient supplements for their child.  
In this sample of New Zealand parents, participants were not accurately representative 
of the New Zealand population. The distribution of ethnicities in New Zealand in 2006 were 
NZ European 67.6%, Maori 14.6%, Australian 0.7%, Other European 2.5%, Asian 8.8%, Pacific 
Island 6.6% and Other 0.9% (Statistics New Zealand, 2006). The distribution of ethnicities in 
this sample were New Zealand European (88%), with the next biggest ethnicity groups being 
Other European followed by Maori. These participant characteristics indicate an over-
representation of NZ Europeans in this sample. This reduced diversity in survey respondents 
will limit the usefulness of the survey findings when used in some settings. An example of a 
setting where the survey results may have restricted use is if the results are being applied to 
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identify ethnicity groups that are low micronutrient users, possibly to target specific groups 
for the purpose of introducing micronutrient supplementation as a treatment option.  
 Another limitation of this study is sample selection bias. The sample of parents in 
this study may have been a selected sample from a group of higher income earners as 
participants had to have access to a computer. The sample may also contain more parents 
interested in the effects of micronutrients. Both of these groups may be more likely to 
purchase a micronutrient supplement for their child. If this has occurred, the demographic 
characteristics may be skewed and the percentage of New Zealand parents who give their 
child a micronutrient supplement may also be higher than in a balanced New Zealand cross 
section. The demographics of parents and percentage of micronutrient users, was not 
however the main aim of the survey investigation and these imbalances should not have 
affected the reported motivations of parents who purchase micronutrient supplements. 
4. Implications and Future Directions 
4.1. Implications 
There is a large difference in the daily cost of providing a child with a research 
standard micronutrient supplement compared to a standard commercial supplement, and it 
is unlikely parents are willing to pay for the higher doses. This theory is supported by the 
survey finding that for New Zealand parents price was the most influential factor when 
choosing a multivitamin supplement for their child. This is a concern. Research has shown 
that nutrients including saturated fats, trans-fats and added sugars that are associated with 
higher disease risk are also associated with lower diet cost (Aggarwal, Monsivais, & 
Drewnowski, 2012). Conversely, they also showed that nutrients such as dietary fibre, 
vitamins A, C, D, E and B12, folate, iron, potassium and magnesium, are associated with 
higher diet costs, and a lower risk of chronic disease. These findings indicate that lower 
intakes of beneficial nutrients are associated with lower diet costs. Aggarwal, Monsivais and 
Drewnowski (2012) found that persons with lower cost/lower quality diets were more likely 
to be from lower socioeconomic (SES) groups, a concerning association as it suggests that 
the SES groups most in need of micronutrient supplementation in their diet, may currently 
be the least likely to purchase a micronutrient supplement. 
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 In order for micronutrient supplements to be a viable dietary option for New Zealand 
parents trying to help their child improve their cognition or psychological symptoms, the 
overall cost of effective micronutrient supplements would need to be significantly reduced 
as sustaining the cost of these effective nutrients over a prolonged period of time may be 
difficult for many families. The approximate cost of an effective supplement for use in 
targeting physical health or mental health issues would be $207 monthly, an amount that 
may be unlikely to be paid by New Zealand parents for whom the most influential factor on 
their supplement purchasing may be price. The consumer market is currently paying on 
average for an over the counter supplement, $19.20 monthly. The monthly cost of giving a 
research grade supplement to a healthy child without targeting physical or mental health 
symptoms using eight EMPowerlpus capsules taken daily as a reference, would be 
approximately $102, which continues to be much greater than current over the counter 
supplement costs. Government or insurance subsidisation would be one way to decrease 
supplement costs for families. Before support in the form of a subsidy could be explored, 
extensive randomised controlled, double blind testing of micronutrient supplements would 
be necessary, in order for micronutrient supplements to be recognised as a viable treatment 
option with proven efficacy.  
 It is important that the public are aware of micronutrient supplements as a possible 
treatment option or supplementary treatment option for mental or emotional symptoms. 
Micronutrients provide a natural treatment option for children, that in some cases can 
enhance pharmacological drug effects (Simpson et al, 2011), or can act on their own to 
significantly improve psychological symptoms. Another benefit of micronutrient 
supplements is if a child has any other concerning health disorders or diseases for which 
they are already receiving treatment, a micronutrient supplement used to treat 
psychological symptoms may be less likely than the alternative pharmaceutical intervention 
to interact with pharmaceutical medications already taken by the child. Although parents 
were able to provide multiple reasons for which they purchase a micronutrient supplement 
for their child, the survey revealed that the majority of New Zealand parents are likely not 
aware of the psychological benefits that micronutrients can provide. If future research 
findings continue to support the efficacy of micronutrients when used in a psychological 
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treatment setting, then a concerted effort should be made by practitioners to provide 
micronutrients as a treatment option to their patients. 
4.2. Future Directions 
Future research may initially focus on determining how micronutrient supplements 
can cause behavioural change. The mechanism by which these supplements are achieving 
the significant results found in most of the research to date, may be contributable to what is 
called a ‘pharmacological cocktail’ effect (ie. when a mixture of chemicals is required for an 
effect). Micronutrient supplements vary in both ingredients and dosages which makes it 
difficult to identify the best micronutrient supplement composition, but an advantage of 
these varied supplements is that they do provide a point of comparison to help identify 
which nutrients may be essential. To identify the most effective nutrient combinations 
extensive testing is required of different nutrient combinations at different dosages, 
achieved through eliminations and additions of ingredients; and dose reductions and 
increases until a formula which optimises results is found. 
The next stage of micronutrient research may focus on the best approach to 
micronutrient supplements used in a treatment setting. One approach to micronutrient 
supplement treatment would be to identify the most effective combination of nutrients and 
their dosages in relation to the treatment goal. For example, a micronutrient supplement 
used in the context of mood disorders might have a different composition to the 
micronutrient supplement used in the treatment of anxiety disorders.   
Another possible approach to the use of micronutrients as a treatment for 
psychological symptoms or improving cognition, is to use the supplement as a nutrient 
balance correction tool. It is possible that nutritional status influences the response to 
supplementation as hypothesised by Schoenthaler and Bier (1999) and Schoenthaler et al. 
(1991; 2000). Therefore in some studies perhaps those that did not respond to 
supplementation had a better diet. The reason micronutrient formulae demonstrates 
benefits may be due in part to an underlying dietary inadequacy. This theory is supported by 
human physiology and nutrition theory, which shows that cellular brain functioning is 
partially dependant on nutritional status (Essman, 1987). This requires further research as 
not all studies have supported this theory (Osendarp et al. 2007). Exploration of this 
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possibility requires further blood tests to identify nutrient imbalances in the individual and 
following this, the micronutrient supplement would be tailored to the individual to correct 
these imbalances. 
Replications of effective research studies are also required for the advancement of 
micronutrients used as a psychological treatment. These replications need to assess affects 
over an extended period of time, and continue to explore the reduction in the amount of 
supplement administrated over longer periods. Further exploration into the maintenance of 
treatment effects with reduced supplement intake, is important from a cost perspective for 
the family, and for the child. In the long term it will mean that a child will not need to 
swallow as many pills. In one of the research studies, the number of pills administered to a 
child once their symptoms reduced significantly was reduced to 25% of the full dose, and 
the significant behavioural changes were found to be maintained two to three years 
following the end of the study (Kaplan et al., 2002). 
Further research with a balanced cross section of New Zealand parents in terms of 
household income and ethnicity may need to be carried out. This research would be 
necessary to confirm that the motivational reasons identified are representative of how all 
groups of New Zealand parents think. It would also provide a more accurate picture of the 
prevalence of micronutrient use among children in New Zealand, which would be helpful 
when using this study to guide the targeting of groups if wanting to provide micronutrient 
supplements as a treatment option. Future research should also assess in more detail the 
perceived benefits of micronutrients, by asking specific questions. For example, a follow up 
question if a respondent indicated a perceived cognitive improvement in their child may be: 
in which of the following cognitive areas have you perceived an improvement; language, 
memory, perception, categorisation or thinking?  This research should also examine why 
parents do not buy their child a micronutrient supplement, which would provide further 
insight as to how much New Zealand parents know about the roles of micronutrients, which 
would help to guide practitioners if they wanted to recommend micronutrients, in their 
approach to introducing micronutrients as a treatment option.  
The attitude towards dietary supplements by journals needs to adjust in support of 
the furthering of supplement research. This is necessary in order to attract the monetary 
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support for further micronutrient research and to increase the public awareness of dietary 
supplements as an effective psychological treatment. The approach by journal publications 
towards dietary supplements has been found to have a relationship with the amount of 
pharmaceutical advertising in a journal (Kemper & Hood, 2008). In an analysis of 11 major 
medical journals, increased pharmaceutical advertising was found to be associated with 
fewer published articles about dietary supplements, and the publishing of more articles with 
conclusions that dietary supplements are unsafe (Kemper & Hood, 2008). These obstacles to 
both funding and publishing this type of work should be removed, as micronutrient 
supplements continue to demonstrate reduced adverse side effects (Katz et al. 2010; Mehl-
Madrona et al. 2010; Simpson et al. 2011) and effective results in psychologically based 
research. 
5. Conclusions 
The current study has investigated the composition of micronutrient supplement 
ingredients, the use of micronutrient supplements by New Zealand children, and through a 
literature review has shown that micronutrient supplements effectively ameliorate a wide 
range of behaviours in children. This research has demonstrated that micronutrient 
supplements found to be effective in research with a child based psychological focus in 
general have significantly greater vitamin dosages than commercially available supplements.  
Furthermore, it was found that micronutrient supplements are not generally given to New 
Zealand children for psychologically based purposes.  
As observed in the current study, comparing the ingredients and dosages in 
micronutrient supplements is a complex process, and although significant differences were 
identified, the accuracy of these values are not absolute. Therefore future research aiming 
to establish the exact values of vitamins and minerals contained in supplements is needed. 
In the calculation process this would require taking into account the absorption of different 
forms of nutrients and the nutrient components in other ingredients. 
 Assessing the efficacy of micronutrient formulas will require extensive research. It is 
likely that eventually different micronutrient supplements will be formulated for which the 
safety and efficacy are optimised to the metabolic requirements of treating different 
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disorders, different individuals, different ages, and different co-morbid health situations 
(Popper, 2001). 
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Appendices 
Appendix A 
    
Statement of Voluntary Consent   
 
To participate in the study described below. 
Name of Study: Examination of Micronutrients for Children: their ingredients, the 
  parents who purchase them, and the role they play in psychological 
well-being. 
 
Purpose of the Study: To better understand parent’s motivations when giving their 
   child a micronutrient supplement, and the factors that influence 
their purchasing of  micronutrient supplements. 
Any questions, feel free to contact either of the primary researchers. 
Primary Researchers:  Amy Harris and Julia Rucklidge. 
 
Contact Information: Department of Psychology 
    University of Canterbury 
    Private Bag 4800  
Christchurch 8140 
 
arh85@uclive.ac.nz 
   julia.rucklidge@canterbury.ac.nz 
The estimated time of completion for this survey is 5 minutes, although this time can 
vary depending on the participant. 
As a volunteer participant in the above mentioned research, I understand that I will 
be asked to complete a survey that will ask questions related to my households use 
of micronutrients and my feelings surrounding this. It will also ask questions of a 
demographic nature. This is to estimate how representative the sample is, of the NZ 
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population. I also understand that I may consider some of the questions personal in 
nature but that the information I provide will be used exclusively for this study and 
will in no way be associated with my name, computer log-in or any other identifiable 
information. 
This survey is a part of the completion of an MSc thesis, which will be a public 
document accessible via the UC library database. 
 
Participants who do not have children are not eligible to complete this survey. 
By clicking “I Agree”, I state that I have read this consent form in its entirety and that 
I understand that I am able to exit the survey at any point, without saving, and 
without consequence.  
o I Agree   
    
o I Do Not Agree   
 
 
This study has been approved by the Human Ethics Committee at the University of 
Canterbury. 
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Appendix B 
 
Child Multivitamin and Mineral Use Survey 
 
 
 
1. How many children currently reside in your household? Note: A child is defined as any 
person under the age of 18. 
If there are no children living in your household you will automatically exit the survey at this point. 
 0  
 1  
 2  
 3  
 4 or more   
 
2.     Are you a male or female?  
 Female  
 Male   
 
3.    What is your date of birth? (DD/MM/YYYY) 
________________________ 
  
4.       What is your marital status?  
 Married  
 Divorced  
 Separated  
 Single  
 De Facto  
 Civil Union  
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 Widow   
 
5.       Which ethnicity/ethnicity's do you most strongly identify yourself with? (Please select 
all that apply)  
 New Zealand European  
 Other European  
 Maori  
 Samoan  
 Cook Islands  
 Tongan  
 Chinese  
 Indian  
 Japanese  
 Korean  
 Other (Please Specify)   
6.     Do you live in New Zealand?  
 Yes  
 No   
 
7.      What is the age or ages of the children living in your household? Choose all categories 
that apply.  
 0-2 yrs  
 3- 4 yrs  
 5- 6 yrs  
 7-8 yrs  
 9- 10 yrs  
 11- 12 yrs  
 13- 15 yrs  
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 16- 18 yrs  
 
8.    Do any of the children in your household have any of the following? 
 Dyslexia  
 Attention Deficit Hyperactivity Disorder (ADHD)  
 Attention Deficit Disorder (ADD)  
 Mood/ Bipolar Disorder  
 Depressive Disorder  
Asthma 
Allergies 
 Autism  
 Aspergers  
 Bed wetting  
 Auditory Processing Disorder  
Downs Syndrome 
 Other (please specify)   
 
9.      Do any of the children in your household take multivitamins?  
 Yes  
 No   
10.   Do any of the children in your household take any other type of supplement? Choose all 
categories that apply.  (If answered no to question nine, participants were sent to question 
eighteen after answering question ten). 
Note: A child is defined as any person under the age of 18. 
 Fish oil/ Omega 3  
 Vitamin C  
 Echinachea  
 Immunity booster  
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 Other (please Specify)   
 They do not take any supplements  
 
 
11.       For approximately how long have they taken a multivitamin?  
 Days  
 Weeks  
 Months  
 A year  
 Years  
 Don't Know   
 
12.       Do they generally take the recommended dosage of their multivitamin? Note: This 
question is asked as an aspect of this research is investigating whether the recommended 
dosage is effective. 
 Yes, they generally take the recommended dosage  
 No, they generally take more than the recommended dosage  
 No, they generally take less than the recommended dosage  
 They generally take more than the recommended dosage only when feeling sick   
 
13.       For what reasons do you buy your child(ren) a multivitamin? Choose all categories that 
apply.  
 It gives me confidence that they are getting a balanced diet  
 The doctor recommended multivitamins  
 Prevention of colds or illnesses  
 To improve my child's mental acuity (i.e their intelligence, cognition)  
Because I was given a multivitamin as a child 
 My child is a picky eater  
 Because my child suffers from a disease  
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 Because my child is run down  
 Because I read that multivitamins were good for children  
 Because my child has a mental health disorder e.g. ADHD, autism, dyslexia, depression  
 To improve my child's ability to focus  
 Because a fellow parent recommended them  
 To help reduce my child's anxiety  
 Other (Please Specify)   
 Don't Know  
 
14.     What brand of multivitamin do you most often purchase?  
 Healtheries  
 Centrum  
 Blackmores  
 Natures Own  
 Thompsons  
 Radiance  
 Solgar  
 Natures Sunshine  
 Kordel's  
 Nature's Plus  
 Other, (please specify)  _________ 
 Not sure   
 
15.       Is there something specific in the ingredients that you look for, when choosing a 
multivitamin supplement?  
 No  
 Yes. Please specify the ingredient(s)   ___________ 
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16.       What factors are most influential in your choice of multivitamin? Choose all categories 
that apply.  
 Price  
 Brand  
 Convenience or ease of consumption for my child  
 Word of mouth  
 Child's preference in taste  
 Child's preference in packaging  
 Other (please specify)   
 Not sure  
 
17.      Have you perceived any benefits from your child(ren) taking a multivitamin? Choose the 
categories that apply.  
 My child has more energy  
 They get ill less often, or with less severity  
 Their ability to focus has improved  
 Their mental health (for example ADHD) symptoms are reduced  
 My child's recovery from illness is faster  
 They have less anxiety  
 They have improved mental capabilities  
 No, I haven't  
 Other (please specify)   
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18.    What is the highest qualification you have earned?  
 Final year of high school  
 Apprenticeship certification  
 Less than final year of high school  
 Post Graduate Diploma  
 Bachelor's Degree  
 Master's Degree  
 Doctorate  
 Other (Please specify)    
 
19.      In what kind of industry do/did you work? (For example: hospital, at home parent, 
newspaper publishing, child care, mail room, factory work, reception, engine 
manufacturing.) 
________________________ 
 
20.       Roughly what is the household income, before taxes and other deductions, over the 
last 12 months?  
 Less than $5,000  
 $5,000 through $11,999  
 $12,000 through $15,999  
 $16,000 through $24,999  
 $25,000 through $34,999  
 $35,000 through $49,999  
 $50,000 through $74,999  
 $75,000 through $99,999  
 $100,000 and greater  
 Don't Know
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Appendix C:  
An excerpt from my full ingredient micronutrient table. 
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